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1001-5 Implementing the First Nationwide Cardiac Registry 
Audit Program: Results from the ACC-NCDR™ Pilot 
Data Audit Program
Frances F. Fiocchi, Jerry D. Kennett, Tony Hermann, Stephen Dobson, Kristi Mitchell, 
Richard E. Shaw, Kathleen Hewitt, Ralph G. Brandis, American College of Cardiology, 
Bethesda, MD
Background: In 2003, the ACC-NCDR™, in collaboration with the ACC Missouri chapter 
and Missouri’s quality improvement organization (MissouriPRO), piloted a national, on-
site data audit program to ensure data submitted to the registry were interpreted and 
collected accurately.
Methods: MissouriPRO conducted the onsite chart reviews and data abstraction for 7 
Missouri cath labs. Facilities were selected on the basis of having submitted at least two 
quarters of data during a 12-month period. A 10% random sample of patient records 
was generated for each site, for a total of 282. For each record, 41 data elements were 
audited for accuracy. Nurse reviewers were required to attend a formal training session 
and pass an inter-rater reliability testing process. Data originally submitted to the registry 
was compared to the audit. A ﬁnal report was sent to each lab outlining recommended 
nexxt steps to enhance the accuracy of the data.
Results: The average accuracy across all 7 sites was 87.28%; individual sites ranged 
from 84.15% to 89.51%. Average accuracy for each data element was also calculated; 
90% of audited data elements were at least 80% accurate. The accuracy of discharged 
alive was 98.58%.
Site #1 Site #2 Site #3 Site #4 Site #5 Site #6 Site #7
Number of records 
audited 10 50 50 49 23 50 50
Overall Accuracy % 84.15% 89.51% 87.65% 87.66% 87.70% 86.15% 88.20%
Conclusions: Pilot results revealed a consistent level of accuracy for most data elements 
across the seven sites. The results also have led to further enhancements that consider 
approaches to improving data element interpretation, increased documentation during 
the audit process, and broadening the scope of the program.
1001-6 Treatment of In-Stent Restenosis in the Era of Drug 
Eluting Stents: The Rise and Fall of Brachytherapy
Gregory J. Mishkel, Nilesh J. Goswami, John B. Gill, Frank V. Aguirre, Robert W. Ligon, 
Anna L. Moore, Prairie Heart Institute, Springﬁeld, IL, Memorial Medical Center, 
Springﬁeld, IL
Background: We evaluated changes in utilization and outcomes of current interventional 
treatment strategies for in-stent restenosis (ISR) in the era of drug eluting stents (DES).
Methods: Utilization, angiographic, and outcome data between May 1, 2003 and June 
30, 2004 was obtained from our facility’s American College of Cardiology National 
Cardiovascular Data Registry and adjunct DES data registry. Life table analysis of 1-year 
death, myocardial infarction (MI), and target lesion revascularization was performed. We 
excluded patients receiving both DES and brachytherapy (BT) (n=1).
Results: During the study period, we performed 314 percutaneous coronary interventions 
with the indication of ISR out of 3909 total procedures (8%). Treatments included BT 
(98), DES (150, 91% Cypher and 9% Taxus) and other (67). The average length of DES 
per ISR was 21.9mm. In the BT group, the average treatment time was 162 seconds 
and the average radiation dose was 19.8 Gray. There was no signiﬁcant difference in 
patient demographics or in-hospital major adverse cardiac events (MACE). In-hospital 
costs were similar ($13,812 for DES versus $14,787 for BT, p=NS). No statistical 
signiﬁcance was found in one-year mortality, MACE (19% BT, 13% DES), and target 
lesion revascularization (3%).
Conclusions: Our analysis indicates that in-hospital outcomes and costs are similar in 
patients receiving DES versus BT for treatment of ISR. Over time, DES has reduced the 
incidence of ISR treatment and the utilization of BT (see graph). 
1001-7 Baseline Characteristics and In-Hospital Outcomes 
of African-American and White Patients Undergoing 
Percutaneous Coronary Intervention
Amar D. Patel, Aniket Kulkarni, Srikanth Sola, Viola Vaccarino, Tarek Helmy, Emory 
University, Atlanta, GA
Background: There is conﬂicting data regarding the peri-procedural outcomes of African 
American (AA) and White (WH) patients undergoing percutaneous coronary intervention (PCI).
Methods: Between January 2001 and December 2003, 4,252 consecutive PCIs were 
performed on AAs and WHs at Emory University Hospital. Complete information was 
available on 3,779 (89%) of them. Baseline characteristics and in-hospital endpoints were 
compared by race, as well as in-hospital outcomes, including angiographic success and 
procedural success (both per American College of Cardiology (ACC) deﬁnitions), peri-
procedural bleeding, and other in-hospital complications after PCI. 
Results: There were a total of 3,094 patients, of which 382 were AAs (12.3%). Compared 
to WHs, AAs were much younger (59 vs. 65 years; p<0.001) and more likely to be women 
(49% vs. 28%; p<0.001). Despite their younger age, risk factors (RF) for coronary heart 
disease such as hypertension (81% vs. 73%), diabetes mellitus (38% vs. 28%), renal 
insufﬁciency (10% vs. 6%; all p<0.001) and current tobacco use (21% vs. 16%; p=0.01) 
were more common in AAs compared to WHs, except dyslipidemia (62% vs. 67%; 
p=0.02). However, there was no difference in method of presentation (emergent vs. non-
emergent) or length of hospital stay. There was also no signiﬁcant difference in lesion 
complexity (ulceration, calciﬁcation, diffuse disease, thrombus, branch point disease), 
ACC site classiﬁcation, or presence of multi-vessel disease. Angiographic success was 
similar between AAs and WHs after adjusting for pre-procedural RF (OR= 0.86, AA vs 
WH, p=0.48). Similarly, post-procedure there was no signiﬁcant difference in bleeding 
complications (OR=0.51 p=0.075), procedural success (OR=1.03, p=0.843), and 
combined in-hospital complications (OR= 1.2, p=0.449). However, there was a tendency 
for black women to show less procedural success than the other groups (p=0.066 for 
race-gender interaction).
Conclusion: There are dramatic differences in age and risk factors between AA and WH, 
perhaps in part due to differences in access to care or referral patterns. Nonetheless, in-
hospital outcomes after PCI are not different between AA and WH.
1001-54 Percutaneous Mitral Valve Repair for Chronic Ischemic 
Mitral Regurgitation: Real-time 3D echocardiographic 
Study
Masao Daimon, Takahiro Shiota, John Liddicoat, Motoya Hayase, Marc Ruel, William 
Cohn, Steven J. Blacker, A. Marc Gillinov, Cleveland Clinic, Cleveland, OH, University of 
Ottawa Heart Institute, Ottawa, ON, Canada
Background: Chronic ischemic mitral regurgitation (CIMR) is associated with a poor 
prognosis. Although surgical annuloplasty is the standard repair for CIMR, its application 
is limited by high morbidity and mortality. In a sheep model of CIMR, we evaluated the 
short-term impact of a novel percutaneous transvenous annuloplasty device placed in the 
coronary sinus, on MR degree and mitral valvular (MV) geometry with real-time 3D echo.
Methods: We examined 6 sheep with CIMR 8 weeks after induced posterior myocardial 
infarction, and 6 normal sheep. The length and stiffness of the device were optimized 
to reduce anterior-posterior (AP) mitral annular dimension and MR. MV tenting heights 
(MVth) and MV tenting area (MVta) in 3 parallel AP planes (medial, central, and lateral) at 
mid systole were assessed by real-time 3D echo with 3D software.
Results: (Table) In sheep with CIMR, MVth in medial and central planes and MVta in all 
3 AP planes were signiﬁcantly larger than normal, and both MVth and MVta in medial 
plane were signiﬁcantly larger than those in lateral AP plane. The annuloplasty device 
reduced both MVth and MVta in all AP planes and improved asymmetric deformation of 
MV in sheep with CIMR. The annuloplasty device reduced MR jet area from 5.4 ± 2.6 to 
1.3 ± 0.9 cm2 (P < 0.01)
Conclusions: Percutaneous coronary sinus-based mitral annuloplasty reduces CIMR, 
by improving the MV tethering. This suggests the potential clinical efﬁcacy of a new non-
surgical therapeutic approach in patients with CIMR. 
Normal (n=6)
IMR (n=6)
MV geometry Baseline Treatment
MVth (mm) Medial 6.3 ± 1.0 9.5 ± 1.6*,† 6.2 ± 1.2
Central 6.3 ± 1.0 8.8 ± 1.7‡ 5.7 ± 1.5
Lateral 6.5 ± 1.5 7.5 ± 1.4 6.2 ± 1.2
MVta (mm2) Medial 77 ± 5 153 ± 46*,† 93 ± 24
Central 82 ± 8 140 ± 47‡ 88 ± 23
Lateral 80 ± 6 103 ± 23§ 87 ± 26
*p < 0.05 vs lateral; †,‡, and § p <0.01, 0.03, and 0.05 vs normal
.
1001-58 Measurement Of Intraventricular Mechanical 
Dyssynchrony By Tissue Doppler Imaging; Is Time To 
Peak Velocity the Best Parameter for Dyssynchrony?
Chinami Miyazaki, Fletcher A. Miller, Barry L. Karon, Raul Emilio Espinosa, Bijoy K. 
Khandheria, Jae K. Oh, Mayo Clinic, Rochester, MN
Background; Quantiﬁcation of mechanical dyssynchrony is important for selecting 
patients for cardiac resynchronization therapy. Although various dyssynchrony parameters 
derived by tissue Doppler imaging (TDI) are proposed in patients with left bundle branch 
block (LBBB) and impaired ejection fraction(EF), those in normal EF subjects has not 
been clariﬁed. We aim to compare TDI parameters of intraventricular dyssynchrony in 
patient with normal EF and normal conduction to LBBB patients. Methods; 33 patients 
(14; normal EF and normal QRS, 10; normal EF and LBBB, 9; EF<35% with LBBB) were 
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studied by TDI from apical views. Time to peak systolic velocity (Ts), time to systolic wave 
onset (To) and time to systolic wave termination (Te) from Q wave were measured in 12 
basal and mid segments. The maximal difference of Ts, Te and To among 12 segments 
(Tsdiff, Tediff ,Todiff) and standard deviation of each variables in12 segments were calculated. 
Results; Although all parameters are signiﬁcantly larger in overall LBBB patients than 
normal group, Tsdif and Ts-SD had substantial variability in the normal group, and could 
not separate LBBB with normal EF from normal group. However, parameters related To 
could distinguish LBBB with poor EF from the other two groups clearly. Conclusion; Even 
in population with normal EF without conduction delay, there is a considerable variability 
in the time to peak systolic velocity. Further clinical investigations are necessary to identify 
the most optimal dyssynchrony parameter. 
Parameters for dyssynchrony
Nomal normal 
QRS LBBB + normal EF
LBBB + impaired 
EF
P value 
(ANOVA)
Age (years) 55±10 72±8* 65±6* <0.01
QRS width (msec) 96±11 151±15* 164±15* <0.01
Tsdiff (msec) 122±65 160±33 191±21* <0.01
Ts-SD (msec) 38.9±22.4 52.2±12.7 62.0±7.2* <0.01
Todif (msec) 56±30 111±40* 157±52* <0.01
To-SD (msec) 15.3±7.3 30.9±11.5* 44.9±13.1*† <0.01
Tediff(msec) 54±30 116±56* 90±37 <0.01
Te-SD (msec) 14.5±7.5 31.0±15.7* 23.8±9.8 <0.01
*; p<0.05 compared to normal, †; p<0.05 compared to LBBB + normal EF
1001-59 Quantitative Pet Imaging of Age-assocaited 
Myocardial Apoptosis using [18F]ﬂuorobenzyl Triphenyl 
Phosphonium: Correlation with DNA Damage/Repair 
and Apoptotic Index
Igal Madar, Daqing Gao, Hayden Ravert, Lei Chen, Martin Pomper, James Fox, James 
J. Frost, Robert F. Dannals, Chiming Wei, Johns Hopkins University, Baltimore, MD
Background: [18F]Fluorobenzyl triphenyl phosphonium (FBnTP) is a new PET imaging 
tracer that accumulates mainly in mitochondria as a function of the membrane potential, 
and therefore may be useful for detecting loss of mitochondrial membrane potential 
(MMP) associated with myocardial apoptosis. The goal of this study is to characterize 
the accumulation of FBnTP in the myocardium of young and old rats in correlation with 
molecular markers of apoptosis. 
Methods: Myocardial dynamic microPET scans were acquired in anesthetized young 
(6M, n = 3) and old (2Y, n = 3) Zucker lean rats, commenced at the IV administration of 
FBnTP (0.3 mCi). Immunohistochemical staining and western blot analysis was performed 
to determine DNA damage product (8-oxoG), DNA repair enzyme (OGGI), the extent of 
mitochondria-mediated apoptosis (caspase-3) and TUNEL staining. Results: Quantitative 
PET imaging revealed a mean decrease of 44% of FBnTP uptake in old versus young 
rat myocardium. The decrease in FBnTP myocardial uptake in old rats paralleled with a 
near 3-fold increase in mitochondria-mediated apoptosis marker Caspase-3 activation, a 
signiﬁcant increase in apoptotic cells (TUNEL) and DNA damage (8-oxoG) and a decrease 
in DNA repair enzyme (OGGI) (Table: *p<0.05 vs Young rats). Conclusions: These studies 
demonstrate that decreased mitochondrial membrane potential and DNA repair enzyme 
associated with increased myocardial apoptosis and oxidative DNA damage in aging heart. 
Study Young (6M) Old (2Y)
FBnTP(%BW/ID) 5.06±1.43 2.83±0.14*
8-oxoG (%) 0.56±0.10 23.2±5.0*
OGG1 (%) 12.0±4.0 0.22±0.15*
TUNEL (%) 0.20±0.10 25.3±5.0*
Cas-3 (score) 0.9±0.21 3.14±0.24*
1001-60 Echocardiographic Guidance of Percutaneous Repair 
for Mitral Regurgitation with the EvalveÂ® System: 
Lessons Learned From the First 27Cases
Frank E. Silvestry, Susan E. Wiegers, Howard C. Herrmann, Sameer Rohatgi, 
Leonardo Rodreguiez, William J. Stewart, Sunichi Homma, Neil Goyal, Todd Pulerwitz, 
Alan Zunamon, Andrew Hamilton, John Merlino, Randy Martin, Kimberly Krabil, Hal 
Wasserman, Elyse Foster, Ted Feldman, Hospital of the University of Pennsylvania, 
Philadelphia, PA
Background: Percutaneous repair of mitral regurgitation (MR) is an increasingly attractive 
alternative to surgery. We report the experience with echo guidance of this procedure in 
the ﬁrst 27 cases.
Methods: A catheter based transseptal approach is used under echocardiographic and 
ﬂuoroscopic guidance to deliver and attach a clip to the mitral valve leaﬂets, replicating 
surgical edge-to-edge repair. The system (Evalve®) uses a steerable guide catheter 
to precisely manipulate and position a clip that approximates the middle anterior and 
posterior leaﬂet scallops of the mitral valve. The guidance of this procedure requires a 
unique collaboration between echocardiographer and interventionalist. A streamlined 
imaging approach was developed, with both standardized vocabulary and predetermined 
TEE views to optimize communication.
Results: 4 standard TEE views were used: 1) Transgastric basilar LV short axis view at a 
multiplane angle of 0-30o (or transthoracic parasternal short axis, if needed) to align the 
clip arms perpendicular to the line of coaptation, determine system translation, and avoid 
contact with the lateral structures; 2) Mid esophageal (ME) intercommissural view at 45-
70o to determine medial-lateral angulation and axial translation of the delivery system, 3) 
ME long axis view at 130-150o for anterior-posterior angulation compared to the direction 
of antegrade mitral inﬂow, and 4) ME 4 chamber view at 0-30o to determine medial-lateral 
position of the clip. Leaﬂet insertion into the clip is assessed using views 1, 2, and 3. A 
standardized vocabulary based on internal mitral valve landmarks was used to optimize 
communication. Echo provides immediate monitoring of MR and transmitral gradients pre 
and post clip deployment, allowing iterative repositioning of the clip (all patients), and 
placement of a second clip (4 patients).
Conclusions: 1) TEE is essential for guiding catheter-based edge-to-edge repair. 2) 
A streamlined approach to imaging using predetermined standardized views shortens 
procedure time for efﬁcient placement and deployment of the clip. 3) A common vocabulary 
between interventionalist and echocardiographer performing the procedure is essential.
1001-61 Is a Normal Exercise Echocardiogram as Reassuring as 
a Normal Exercise Nuclear Perfusion Scan?
Rohit Bhatheja, Inder Singh, Maran Thamilarasan, Leonardo Rodriguez, Claire Pothier, 
Michael Lauer, Cleveland Clinic Foundation, Cleveland, OH, University of Queensland, 
Brisbane, Australia
Background: A normal exercise echocardiogram may not be as reassuring as a normal 
exercise myocardial perfusion image (MPI).
Methods:  We followed 12,704 patients who had completely normal exercise MPI 
(n=3888) or exercise echocardiography (n=8816) for 5 years. Protocols, personnel, data 
deﬁnitions and acquisition were the same for both types of imaging. We used propensity 
matching to account for 46 possible confounders including prognostically important 
clinical and exercise ﬁndings.
Results: Compared to those who underwent exercise echocardiography, those who 
underwent exercise MPI were older (58 vs. 56 years, P<0.0001), more likely to be men 
(61% vs. 58%, P=0.002), and more likely to have diabetes (10% vs. 7%, P<0.0001) 
or known coronary disease (35% vs. 21%, P<0.0001). We were able to successfully 
propensity match 3213 patients who underwent MPI to 3213 patients who underwent 
exercise echocardiography on all 46 possible confounders. In this propensity-matched 
cohort there were 258 deaths. The ﬁve-year mortality risk among patients who 
underwent exercise MPI was low (4.7%, 95% CI 4.3%-5.1%) and was similarly low 
among patients who underwent exercise echocardiography (4.3%, 95% CI 3.9%-4.8%). 
There was no difference in the mortality risk between the two groups (propensity-
adjusted hazard ratio for MPI patients 1.11, 95% CI 0.86-1.43, P=0.42). (Figure) 
Conclusion: Similar to the case with exercise MPI, a normal exercise echocardiogram 
predicts a low risk of all-cause death over the next 5 years..
1001-62 The Effect of Therapeutic Ultrasound Upon Myocardial 
Perfusion: Assessment by Myocardial Contrast 
Echocardiography
Andrew M. Kahn, Robert J. Siegel, Bruno Cotter, Huai Luo, Felizabel G. Bannach, G. 
Monet Strachan, Anthony N. DeMaria, University of California, San Diego, CA
Previous studies have shown that low intensity ultrasound can improve perfusion of 
ischemic limbs, and enhance blood ﬂow by laser Doppler measurement and surface pH in 
ischemic myocardium. The purpose of this study was to assess the effects of therapeutic 
ultrasound upon myocardial perfusion by contrast echocardiography (MCE). Studies were 
performed in 6 open chest dogs in which one hour of total LAD occlusion was followed 
by one hour of ultrasound at 29 KHz, 30% duty cycle, 1.4 W/cm2 administered to the risk 
area by a prototype device. Real time low energy MCE was performed during continuous 
infusion of Optison using 15 cardiac cycle destroy/reperfusion sequences and subsequent 
videointensity analysis by Q Lab. A laser Doppler ﬂow meter was used to measure local 
tissue perfusion (as TPU). Following one hour of LAD occlusion, risk area MCE intensity 
was reduced by 90%, and the reﬁlling rate was too small to be determined. One hour of 
therapeutic ultrasound exposure produced on average a doubling of MCE intensity, with 
improvement noted in ﬁve of six dogs studied. There was a corresponding mean increase 
of 7% in TPU, and an average rise of less than one degree Celsius in the myocardial 
surface temperature. In conclusion, therapeutic ultrasound improves myocardial perfusion 
to risk area myocardium following coronary occlusion, and may be a valuable adjunctive 
therapy for myocardial ischemia.
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1001-113 Polymorphisms in Lipoprotein and Lipid Metabolism 
Genes Predict Response to Pravastatin Therapy
Marc S. Sabatine, Kausik K. Ray, Hannia Campos, Olga A. Iakoubova, Todd G. 
Kirchgessner, Koustubh Ranade, Zenta Tsuchihashi, Lynn M. Ploughman, Kim E. Zerba, 
James J. Devlin, Peter M. Shaw, Frank M. Sacks, Eugene Braunwald, Brigham and 
Women’s Hospital, Boston, MA
Background: There remains much individual variability in the response to statins. We 
hypothesized that single nucleotide polymorphisms (SNPs) in genes encoding lipoproteins 
and lipid metabolism enzymes may be associated with different magnitudes of response 
to statins.
Methods: The CARE trial randomized 4159 patients with prior MI to pravastatin 40 mg 
qd or placebo. Cholesterol levels were measured by a core laboratory at regular intervals 
over 5 yrs of follow-up. As part of a comprehensive genotyping project, patients were 
genotyped at several loci relevant to lipid trafﬁcking & metabolism.
Results: SNPs in the following genes were identiﬁed: Apo A-IV (chromosome 11q23, 
basepair location 258, amino acid change of Ser to Thr, minor allele frequency 0.20), 
Apo B (2p24, bp 7224, Pro to Leu, 0.22), Apo E (19q13, bp 3018, Arg to Cys, 0.06), 
cholesteryl ester transfer protein (CETP) (16q21, bp 20325, Ile to Val, 0.33), Lp(a) (6q26, 
bp 63, Ile to Met, 0.02). The changes in cholesterol levels from baseline to last value at 
follow-up with pravastatin vs. placebo for each genotype are shown in the ﬁgure along 
with interaction P values.
Conclusions: SNPs in genes encoding lipoproteins and lipid metabolism enzymes 
may explain some of the variation in response to statin therapy. Further characterization 
of these potential pharmacogenomic interactions is warranted. If validated, a panel of 
signiﬁcant genotypes could be used to individually tailor lipid-lowering therapy. 
1001-114 Relationship Between Diabetic Status and Progression 
of Carotid Atherosclerosis After the Addition of 
Extended-release Niacin to Statin Monotherapy
Allen J. Taylor, Hyun Y. Lee, Karen A. Grace, Jeannie K. Lee, Lance E. Sullenberger, 
Walter Reed Army Medical Center, Washington, DC
Background: We previously reported in a placebo-controlled study that extended-
release niacin slowed the progression of carotid atherosclerosis when added to statin 
monotherapy. This analysis examines the relationship between glucose intolerance and 
the effects of niacin on common carotid artery intima-media thickness (CIMT).
Methods: Double-blind, randomized, placebo controlled study (ARBITER 2) of once-
daily extended-release niacin (1000 mg) added to background statin therapy in 167 
patients (mean age 67 years) with known coronary heart disease, mean LDL-C of 89 
mg/dL and low levels of HDL-C (< 45 mg/dL). The primary endpoint was the change in 
CIMT after 1 year. Among 149 that completed the study, 88 had diabetes or the metabolic 
syndrome (DM/MS).
Results: Niacin increased HDL-C to a similar degree (~20%) in both those with and 
without DM/MS. Progression of CIMT was related to both the presence of DM/MS and 
treatment with niacin. (Figure; mean ± 2 SEM; ANOVA P = .037) Placebo-treated patients 
had the greatest CIMT progression, regardless of DM status. The lowest progression rate 
was observed in niacin treated patients with normal glycemic status.
Conclusions: Progression of CIMT was similar among individuals with low HDL-C in 
the setting of either normal or abnormal glycemic control. Niacin was additive to statin 
therapy, particularly among those with normal glycemic control. 
 
.
1001-117 Coenzyme Q10 Improves Myopathic Pain in Statin 
Treated Patients
Patricia Kelly, Sujethra Vasu, Marie Gelato, Margaret McNurlan, William E. Lawson, 
SUNY Stony Brook, Stony Brook, NY
Background: HMG CoA reductase inhibitors (statins) inhibit the enzyme common to the 
synthesis of both cholesterol and coenzyme Q10 (CoQ10; the ﬁrst step in mitochondrial 
ATP production). While statin treatment markedly decreases cardiac events and mortality 
its association with myopathy and pain limits its use. This study examined the effects of 
exogenous coQ10 on statin using patients with myopathic pain.
Methods: A prospective, randomized, blinded trial of vitamin E 400 IU versus CoQ10 
100 mg daily for 30 days was performed in statin patients with myopathic pain, holding 
the dose and type of statin constant. Lipids, creatinine phosphokinase (CPK), and a 
validated tool for pain assessment (0-10 range) were performed at baseline and at 30 
days. Statistical testing pre and post was performed for each group by paired students t 
test and for improvement in pain between groups by the Fisher exact test with signiﬁcance 
at p< 0.05.
Results: There were 20 patients (9 male) randomized to vitamin E and 21 patients (13 
male) randomized to CoQ10. The mean ages, BSA, CPKs and lipid proﬁles at baseline 
were comparable. Pre and post Vitamin E, pain remained unchanged (3.9 ± 2.2 versus 4.4 
± 2.8; p = NS). Pre and post CoQ10, pain improved signiﬁcantly (6.2 ± 1.7 versus 3.1 ± 
2.2; p < 0.001). Pain improved in 3/20 Vitamin E and 18/21 Co Q10 patients (p<0.001).
CPK did not change signiﬁcantly with treatment in either group and did not correlate with 
the severity of pain. LDL did not change signiﬁcantly in either group during treatment 
(102.4 ± 41.0 mg/dl versus 98.7 ± 25.7 with Vitamin E; 94.7 ± 13.4 mg/dl versus 103.3 
± 22.6 with CoQ10). Conclusions: Treatment with CoQ10 improves myopathic pain in 
patients receiving statin therapy. The CPK level within a normal to mildly elevated range 
did not correlate with the severity of myopathic pain. Improvement in myopathic symptoms 
with CoQ10 treatment was not related to changes in the CPK.
1001-151 Beneﬁt of BNP Plasma Levels For Optimising Therapy : 
The Systolic Heart Failure Treatment Supported By BNP 
Multicenter Randomised Trial (STARS-BNP).
Patrick Jourdain, F. Funck, P. Gueffet, H. LeHelloco, E. Donal, J.F Aupetit, M.C. Aumont, 
M. Galinier, G. Jondeau, Y. Juilliere, CH R. Dubos, Pontoise, France, The French Working 
Group on Heart Failure, France
BACKGROUND: We hypothesised that the use of brain natriuretic peptide (BNP) levels 
to optimise medical therapy would improve clinical outcome in patients with systolic 
heart failure optimally treated according to guidelines.
METHODS: 220 patients (NYHA 2-4 and LVEF <45%) followed in 21 hospitals were 
randomised 1/1 to receive either treatment guided by BNP (BNP group) or not (clinical 
group). BNP was used as an indication to increase medical treatment until BNP plasma levels 
lowered below 100 pg/ml. Out-patient visit were scheduled every month for three months and 
every 4 months thereafter.
All patients were optimally treated with ACEI, beta blocker and diuretics before randomisation. 
The 2 groups were comparable in term of NYHA class, clinical examination, Creatininemia, 
Natremia, HF aetiology, systolic arterial pressure and heart rate. LVEF was slightly lower in the 
BNP group than in clinical group (28+-7% vs 31.5+-8.6%; p<0.05). 
RESULTS (ﬁgure): During follow-up (minimum 6-months, median 15 months), there were 
signiﬁcantly fewer events (death or hospitalizations) for heart failure in the BNP group 
than in the clinical group (25 vs 57 p<0,001). At the end of the follow up, 15.6 % of 
patients in the BNP group and 26.8 % in the clinical group had experienced a ﬁrst HF 
event (p=0.001). 
CONCLUSION: In heart failure patients already treated according to guidelines the 
use of BNP to guide medical therapy reduced HF events and delayed time to ﬁrst event 
compared with clinically guided treatment . 
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1001-152 A Blood Pressure-Genotype Interaction in Corin is 
Associated With an Increased Risk of Left Ventricular 
Hypertrophy in Untreated Hypertension
J. Eduardo Rame, Mark H. Drazner, Wendy Post, Joao Lima, Sabine Knappe, Quingyu 
Wu, Daniel L. Dries, Johns Hopkins University School of Medicine, Baltimore, MD, 
University of Texas Southwestern Medical Center, Dallas, TX
Background: Left ventricular hypertrophy (LVH) is a known predictor of cardiovascular events, 
including heart failure. The natriuretic peptide system has been invoked in physiologic counter-
regulation promoting vasodilatation, natriuresis, and attenuating cardiac hypertrophy and ﬁbrosis. 
We hypothesized that individuals who are genotype positive for two novel non-synonymous 
non-conservative single nucleotide polymorphisms in complete linkage disequilibrium in corin, 
the pro-ANP/BNP convertase, would be susceptible to the development of LVH as a result of a 
modiﬁcation of the left ventricular mass (LVM)-systolic blood pressure (SBP) relation. 
Methods: Individuals with comparable cardiac MRI measurements to determine LVM in 
the Dallas Heart Study (DHS) and in the Multi-Ethnic Study of Atherosclerosis (MESA), 
our replication sample, were genotyped at the T555I/Q568P locus using a TaqMan 
assay. Multivariate linear regression models were used to determine the presence of an 
interaction between SBP and corin genotype on LVM in African Americans--the group in 
which the variant was almost exclusively present with a prevalence ~12%--who were not 
on anti-hypertensive medication in DHS (N=913) and MESA (N=636). 
Results: A positive and signiﬁcant interaction between corin genotype and systolic blood 
pressure on LVM was identiﬁed in the DHS (p=0.005) and MESA (p=0.006), independent 
of relevant covariates and measures used to adjust for body size. Individuals with the corin 
variant have an excess increase in LVM of 4 grams per 10 mm Hg of SBP when compared 
to wild-type. A signiﬁcant increase in prevalent LVH (40.0% versus 18.6%, p=0.01) was also 
identiﬁed in the group of untreated hypertensives who were positive for the corin variant, as 
compared to group of untreated hypertensives without a copy of the corin minor allele. 
Conclusion: Strong evidence exists that African-Americans who are genotype positive for the 
corin variant are more susceptible to developing LVH in the setting of untreated hypertension 
than their wild-type counterparts. This increased susceptibility may be the result of a modiﬁcation 
of the LVM-SBP relation enhancing the hypertrophic response to increased afterload.
1001-153 Three Year Follow-Up of the Feasibility and Safety of 
Autologous Myoblast Transplantation for Ischemic 
Cardiomyopathy in Patients Undergoing Coronary 
Artery Bypass Grafting
Nabil Dib, Dean Kereiakes, Patrick McCarthy, Robert MacLellan, Greg Fonarow, Robert 
Michler, Ann Campbell, Diane Buchele, Philip Binkley, Johnothan Dinsmore, Amir 
Gahremanpour, Marwan Gazhoul, Wendy Pollock-Maddox, Loretta Netterville, Edward 
Diethrich, Arizona Heart Institute, Phoenix, AZ
Background: Autologous myoblast transplantation (AMT) to repair myocardial infarction 
has been shown to be safe and effective in preclinical studies. The objective of this study 
was to demonstrate the safety and feasibility of myoblast transplantation in humans.
Methods: Twenty two patients scheduled to undergo elective coronary artery bypass graft 
(CABG) were enrolled in the US multicenter clinical trial over 3 years. Subjects with previous 
myocardial infarction and a left ventricular ejection fraction <40 % were eligible to participate. 
The mean age of patients was 54±11 years. The average baseline ejection fraction (EF) 
was 22.9 %. A skeletal muscle biopsy between 2-5 grams was excised from each patient’s 
quadriceps to isolate and expand myoblasts over 2-5 weeks. Purity of the cells ranged from 
47 to 98% CD56+ myoblasts. Between 3 and 30 direct injections (0.1ml/ inj) were delivered 
into the area of infarction using one of 4 escalating doses ranging from 10 to 300 million 
cells. Pre and post-injection ECG, echocardiogram, Holter monitoring, positron emission 
tomography (PET) and magnetic resonance imaging (MRI) were performed. 
Results: The cells were delivered in all subjects without perioperative complications. 
Echocardiography, PET and MRI scans showed evidence of viability in the area of the grafted 
scar. The mean EF by echocardiography improved from 22.9% to 34.6% (p=0.001) at 24 
months follow up. The NYHA class improved from 2 to 1.5. Two events of non-sustained 
ventricular tachycardia, possibly related to cell transplant occured within the ﬁrst two weeks 
after procedure. One death occured due to graft thrombosis on the 12th post-operative day.
Conclusion: Results of the ﬁrst US multicenter clinical trial indicate that AMT in patients 
undergoing CABG is feasible and safe. Improvement in viability is encouraging and 
warrants future clinical trials evaluating the effect of AMT on left ventricular function. A 36 
month follow-up will be presented.
1001-154 Comparison Of Two Methods Of Peripheral Blood 
Stem Cell Transplantation In Patients With Myocardial 
Infarction: Intracoronary Infusion Of Mobilized 
Peripheral Blood Stem Cell Vs. Mobilization Only[Magic 
Cell Investigator: Myocardial Regeneration And 
Angiogenesis With G-CSF Mobilization And Intra-
coronary Infusion Of Stem Cell]
Sang-Hoon Na, Hyun-Jai Cho, Jin-Wook Chung, Joo-Yong Hahn, Hae-Young Lee, 
Hyun-Jae Kang, Young-Seok Cho, Bon-Kwon Koo, Yong-Jin Kim, Tae-Jin Youn, Dae-Won 
Sohn, Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Yun-Sik Choi, Hyo-Soo Kim, 
Seoul National University Hospital, Seoul, South Korea
BACKGROUND: Intracoronary[IC] infusion of peripheral blood stem cells[PBSC] mobilized 
with G-CSF stimulation has been shown to improve cardiac function in patients with myocardial 
infarction[MI].We evaluated feasibility and therapeutic efﬁcacy of G-CSF induced stem cell 
mobilization and subsequent intracoronary infusion of mobilized PBSC in MI patients. 
METHODS AND RESULTS: We prospectively randomised 42 patients with MI who 
underwent coronary stenting for the culprit lesion of infarction into three groups; cell 
infusion(n=10),G-CSF alone(n=17),and control group(n=15).Patients in G-CSF group and 
cell infusion group received G-CSF with dose of 10 µg/kg for 4days and then collected 
PBSC with apheresis were infused via IC route in the cell infusion group.We evaluated 39 
patients who completed at least 6months’ follow-up.No symptoms or signs of signiﬁcant 
ischemia or arrhythmia during peri-apheresis procedure. LV systolic function improved 
signiﬁcantly in cell infusion group(LVEF baseline:last follow up; 48.9±8.9:56.7±6.8%, 
p=.003).There was no signiﬁcant improvement observed in G-CSF alone and control grou
p(53.5±13.0:54.0±10.7%, p=.85 and 47.6±8.5:50.2±9.9%,p=.15).Sustained improvement 
was observed in cell infusion group only till 1 year(48.9±8.9:56.4±6.7%,p=.023).Regions 
of hypoperfused myocardium measured by SPECT were reduced at 6 months from 
12.7±10.0% to 7.9±9.2%(p=.00)and this effect sustained till 1 year(7.4±9.6%). In-stent 
restenosis rate at 6 months was higher in cell infusion and G-CSF alone group than 
control (5/10:7/14:3/15, p=.17) without angina aggravation, MI or death at 6 months.
CONCLUSIONS: G-CSF induced mobilization and IC infusion of mobilized PBSC are 
feasible methods for stem cell transplantation in MI. PBSC transplantation after PCI 
improved systolic function. G-CSF with additional IC infusion of collected PBSC is a better 
method of PBSC transplantation than mobilization only in patients with MI. Improvements 
with PBSC transplantation were maintained at least till 1 year after transplantation. G-
CSF might aggravate in-stent restenosis. Results from long term follow up and large 
randomized trial are required.
1001-155 Complex Anabolic Deﬁciency Is Related To Clinical 
Severity And Increased Mortality In Men With Chronic 
Heart Failure
Ewa A. Jankowska, Bartosz Biel, Jacek Majda, Stephan von Haehling, Waldemar 
Banasiak, Piotr Ponikowski, Cardiology Department, Military Hospital, Wroclaw, Poland, 
Institute of Anthropology, Polish Academy of Sciences, Wroclaw, Poland
Background: Male aging is accompanied by anabolic depletion (total testosterone [TT], 
dehydroepiandrosterone sulphate [DHEAS], insulin-like growth factor 1 [IGF1]) which is 
related to increased morbidity and mortality. We investigated its clinical and prognostic 
signiﬁcance in male patients (pts) with chronic heart failure (CHF)
Methods. Serum levels of TT, DHEAS, IGF1 were assessed by immunoassays in 126 male 
CHF pts (age:61±1y, LVEF:32±1%, NYHA class I/II/III/IV:12/68/38/8, peakVO2:14.5±0.5mL/
min/kg). Reference group consisted of 499 healthy men aged 35-80.
Results. Men with CHF showed a deﬁciency in DHEAS, IGF1 (not TT) as compared to 
age-matched controls (56%, 71%, 97% of reference values). When CHF pts were divided 
according to CHF severity, substantial differences were revealed in all hormones (NYHA 
I/II/III/IV: TT:108/104/91/40%; DHEAS:105/55/50/24%; IGF1:74/70/72/66%. Gonadal 
andropenia (TT<3ng/mL), adrenal andropenia (DHEAS<600ng/mL), IGF1 deﬁciency 
(IGF1<200ng/mL) were observed in 25%, 51%, 49% of CHF pts, vs 9%, 3%, 3% of controls 
(p<0.0001). NYHA class was related to TT, DHEAS (r=-0.30, r=-0.35, both p<0.001), but 
not IGF1. Peak VO2 correlated with TT, DHEAS (r=0.24, r=0.31, both p<0.05), but not 
IGF1. TT (not DHEAS, IGF1) correlated with leg and arm lean mass (r=0.30, r=0.25, both 
p<0.05), but not with fat mass. During follow-up (21±1 months) 15 (12%) CHF pts died. In 
a univariate Cox analysis, IGF1 (p=0.01), DHEAS (p=0.004), TT (p<0.001), age, NYHA 
class, peak VO2, serum creatinine (all p<0.05) were related to survival. In multiple models, 
independently TT (p=0.01) and DHEAS (p=0.03) and borderline IGF1 (p=0.08) remained 
prognostic markers, even when adjusted for confounders. In CHF pts with TT, DHEAS 
and IGF1 deﬁciency the 18-month survival rate was 65%, 74%, 76%, compared to 92% 
(p<0.001), 96% (p=0.001), 96% (p=0.01) in men without anabolic depletion.
Conclusions. IGF1 deﬁciency and adrenal andropenia are found in 50%, as gonadal 
andropenia - in 25% of CHF men. Complex anabolic deﬁciency is related to CHF severity 
and predicts poor outcome. Whether a pharmacological correction of anabolic depletion 
might be another therapy in CHF men, remains further studies.
1001-184 A Comparison Of Quality Of Life Scores In Patients With 
Angina Pectoris After Medical Treatment Compared With 
Angioplasty And Coronary Bypass Surgery: Outcomes 
Of A Randomized Clinical Trial (MASS I I)
Myrthes Takiuti, Jurema Palomo, Priscyla Girardi, Teryo Nakano, Aecio Gois, Desiderio 
Favarato, Neuza Lopes, Whady Hueb, Sergio Oliveira, Luis Cesar, Jose Ramires, Heart 
Institute(InCor) University of Sao Paulo, São Paulo, Brazil
Introduction: Although medical treatment (MT), coronary angioplasty (PCI) and 
coronary bypass surgery (CABG) are traditionally performed, the need to assess the 
patients’ quality of life (QOL) has been regarded with increasing importance. Although 
QOL instruments have been used to assess the efﬁcacy of a therapeutic intervention, 
they have not been used previously to compare the impact of medical treatment with that 
of PCI or CABG in patients with stable angina.
Background: This study sought to compare QOL scores during three years in patients 
with stable angina and preserved ventricular function submitted to one of these treatments: 
MT, PCI or CABG.
Methods: A total of 611 patients were randomly assigned to either a CABG (n = 203), 
PCI (n = 205), or MT (n = 203) group. The one-year survival rates were 96.0% for CABG, 
95.6% for PCI, and 98.5% for MT. The Short Form Health-Related QOL Questionnaire 
(SF-36) was used to assess the quality of life of the patients. The SF-36 comprises 36 
questions that measure eight dimensions of health: physical functioning, role limitations 
due to physical health, bodily pain, general health, vitality, social functioning, role 
limitations due to emotional health, and mental health. Before randomization and at 
12, 24 and at 36 months, patients completed the questionnaire. We compared the QOL 
in baseline evaluation and during the follow-up among groups related to each kind of 
treatment. Comparisons between the groups were made with a t test.
Results: At baseline, there were no differences in QOL between treatment groups. At 
the 6-month follow-up visit, there was improvement in all groups compared to baseline 
evaluation, with no difference related to the treatment. At the 12, 24 and 36-month 
evaluation, the improvement observed at 6 months persisted and was not statistically 
different between groups (MT, PCI or CABG).
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Conclusion: In this study, patients with stable coronary disease and preserved ventricular 
function submitted to MT, or PCI or CABG had improvement in QOL, detected in 6 months 
which persisted for 36 months. MT, PCI and CABG are both safe methods of treatment of 
coronary disease in considering improvement of QOL.
1001-210 Platelet Derived Growth Factor Receptor (pdgfr)-β 
Signaling Regulates Vascular Maturation In Healing 
Myocardial Infarcts
Pawel T. Zymek, Anna Cieslak, Sophia Tincey, Guofeng Ren, Lloyd H. Michael, Mark L. 
Entman, Nikolaos G. Frangogiannis., Baylor College of Medicine, Houston, TX
During the maturation phase of healing, infarct microvessels are coated by pericytes, 
whereas uncoated vessels regress. Acquisition of a muscular coat leads to formation of 
a mature vasculature preventing uncontrolled angiogenesis and decreasing leukocyte 
extravasation. Platelet Derived Growth Factor Receptor (PDGFR)-β interactions are crucial 
for coating of developing fetal vessels with pericytes. Accordingly, we examined the role 
of PDGF in maturation of infarct neovessels. A canine and a murine model of reperfused 
infarction were used. To study the role of PDGF in infarct healing, mice undergoing infarction 
protocols were injected daily with a neutralizing anti-PDGF antibody, the neutralizing anti-
PDGFRβ antibody APB5, or vehicle and were sacriﬁced after 7 days of reperfusion.
Canine infarcts showed a progressive increase in the number of pericyte-coated vessels after 
2-4 weeks of reperfusion. In murine infarcts the healing rate is faster and maturation of the 
vasculature occurred after 7 days of reperfusion. PDGF expression was localized in infarct 
microvessels, whereas many PDGFRβ expressing pericytes were identiﬁed in dog infarcts 
after 5-14 days and in mouse infarcts after 3-7 days of reperfusion. PDGF neutralization and 
PDGFRβ blockade induced similar morphological alterations of the infarct microvasculature 
leading to formation of a higher number of uncoated vessels (p<0.05) and a higher capillary 
density (p<0.05). Uncoated vessels in antibody-treated animals were dilated and irregular 
and were associated with areas of red blood cell and inﬂammatory leukocyte extravasation, 
suggesting increased permeability. Inhibition of PDGFRβ signaling induced increased and 
prolonged macrophage extravasation in the healing infarct (p<0.01). PDGF expression 
in healing infarcts has a critical role in vascular coating and maturation and is important 
for stabilization of the scar and suppression of inﬂammatory cell extravasation. PDGFRβ 
blockade results in formation of a chaotic hyperpermeable vasculature leading to prolonged 
extravasation of blood cells into the infarct.
1001-211 Effects of Mesenchymal Stem Cells Transduced with 
Akt on Porcine Myocardial Infarction
Youngkeun Ahn, Sang Yup Lim, Myung Ho Jeong, Kwang IL Nam, Yong-Sook Kim, Min 
Cheol Lee, Ho Chun Song, Young Jun Hur, Min Cheol Lee, Eun Hui Bae, Young Joon 
Hong, Jeong Gwan Cho, Eun Hui Bae, Jong Chun Park, Jung Chaee Kang, Anthony 
Rosenzweig, Takashi Matsui, Chonnam National University Medical School, Gwangju, 
South Korea, Massachusetts General Hospital, Boston
Background: Bone-marrow-derived Mesenchymal stem cells (MSCs) are self-renewing, 
clonal precursors of non-hematopoietic tissues and can differentiate into cardiac muscle 
in vitro and in vivo. However, transplantation of MSCs into infarcted porcine hearts yields 
only marginal improvement in cardiac function. This study was designed to examine 
whether MSCs transduced with Akt, a serine-threonine kinase and potent pro-survival 
signal in many systems, are more resistant to apoptosis and enhance cardiac repair after 
transplantation into the ischemic porcine heart. 
Methods and Materials: We separated MSCs from hematopoietic cells based on 
their preferential attachment to polystyrene surfaces. We genetically engineered MSCs 
using ex-vivo myr-Akt-adenoviral gene transfer. MSCs were delivered by intracoronary 
injection to pigs after myocardial infarction (MI) [group I (control: n=5), media only; group 
II (n=5), MSCs only; group III (n=5), MSCs modiﬁed with Akt]. Myocardial SPECT was 
performed before and 4 weeks after MSC transplantation and pigs were sacriﬁced for 
immunocytochemical characterization using CD34 (ICO115), integrin αV, Vimentin, and 
α-sarcomeric actin and further histologic analysis for apoptosis and ﬁbrosis. 
Results: Mean LV ejection fraction (EF) was 44.8±16.6 %, 29.8±7.6 %, and 41.2±8.3 % 
at ﬁrst (each n=5) and changed to 29.8±8.5 %, 39.0±9.5 %, and 60.1±17.4 % at 4 weeks 
after the MSC implantation in group I, II, and III respectively. Mean MI area was 17.6±9.2 
%, 35.0±11.8 %, and 24.3±11.2 % at ﬁrst, and changed to 19.6±10.1 %, 27.2±13.9 %, 
and 7.4±5.3 % in group I, II, and III respectively. Transplantation of ~107 cells into the 
ischemic porcine myocardium in group II increased the ΔLV EF (-14.9±15.3 % versus 
9.0±8.6 %, n=5 in each, p=0.016) and decreased the Δarea of MI (2.1±1.3 % versus 
-7.9±9.0 %, n=5 in each, p=0.04) compared with control group and much more different in 
group III in ΔLV EF (19.2±16.4 %, p=0.006) and in Δarea of MI (-16.3±6.4 %, p=0.037). 
Conclusion: MSCs transduced with Akt enhance repair of the injured area, prevent 
remodeling, and restore systolic performance in infarcted hearts.
1001-212 Lipid-Rich and Ruptured Plaques Are Characterized by 
Complex Microvessels With Sprouting and Abundant 
Peri-vascular Inﬂammation: Understanding Novel 
Links Between Neovascularization and High-Risk 
Atherosclerosis.
K-Raman Purushothaman, Pedro R. Moreno, William N. O’Connor, Annapoorna S. Kini, 
Samin K. Sharma, Valentin Fuster, Mount Sinai Medical Center, New York, NY, University 
of Kentucky, Lexington, KY
Background: Although high-risk atherosclerosis is associated with increased 
neovascularization, speciﬁc neovessel morphology has not been systematically studied. 
This study was designed to describe a morphologic classiﬁcation of neovessels in ﬁbro-
calciﬁc, lipid-rich and ruptured atherosclerotic plaques.
Methods: Neovessel morphology was identiﬁed in 530 microvessels from human aortic 
plaques using CD-34 immunostaining linked to a blue chromogen. Macrophages and T 
cells were identiﬁed by CD-68/CD-3 immunostaining linked to a red chromogen. Three 
different neovessel patterns were clearly identiﬁed, including tubulo-luminal neovessels 
(circular, oval and elongated morphology), sprouting neovessels, and neovessels with 
abundant peri-vascular inﬂammation. (See Figure, lower panel).
Results: Tubulo-luminal morphology was increased in neovessels from ﬁbrocalciﬁc 
plaques when compared to neovessels from lipid-rich or ruptured plaques (P=0.0001). 
However, complex neovessel morphology including sprouting and abundant peri-vascular 
inﬂammation was increased in lipid-rich and ruptured plaques when compared to 
ﬁbrocalciﬁc plaques (P=0.0001 for both comparisons; See Figure, upper panel).
Conclusion: Lipid-rich and ruptured plaques are characterized by complex microvessels 
with sprouting and abundant leakage of inﬂammatory cells. These results provide novel 
links in the understanding of neovascularization and high-risk atherosclerosis. 
1001-213 Early Treatment for Non-ST-Segment Elevation Acute 
Coronary Syndromes is Associated with Appropriate 
Discharge Care: The CRUSADE Experience
W. Brian Gibler, Eric D. Peterson, Matthew T. Roe, James W. Hoekstra, Sarah Milford-
Beland, Deborah B. Diercks, Charles V. Pollack, Jr., W. Frank Peacock, Gregory J. 
Fermann, Richard Summers, E. Magnus Ohman, University of Cincinnati, Cincinnati, 
OH, Duke Clinical Research Institute, Durham, NC
Background Acute treatment, deﬁned as therapy given within the ﬁrst 24 hours, is 
associated with improved outcome in-hospital for patients with non-ST-segment elevation 
acute coronary syndrome (NSTE ACS). We hypothesize that patients who receive 
appropriate, aggressive treatment within the ﬁrst 24 hours after hospitalization, are more 
likely to receive guidelines-indicated therapy on hospital discharge.
Methods We evaluated the use of aspirin (ASA), beta-blockers (BB) and clopidogrel 
(clopid) in the ﬁrst 24 hours as well as on hospital discharge in accordance with the 
2002 ACC/AHA Guidelines for NSTE ACS. We compared the relationship between acute 
ASA therapy given in the ED, acute ASA therapy not given in the ED, and no acute ASA 
treatment in 6,383 eligible high-risk patients from the CRUSADE quality improvement 
initiative with positive cardiac biomarkers or ischemic ST-segment changes on ECG. 
Similarly, we evaluated BB therapy in 7,272 and clopid treatment in 10,868 high-risk 
patients presenting to over 300 hospitals across the US.
Results Patients who received acute ASA in the ED, ASA in the ﬁrst 24 hours but not in 
the ED, and eligible patients that didn’t receive acute ASA therapy had discharge ASA 
treatment rates of 91.61%, 91.25%, and 53.23%, respectively (p<.0001). Patients eligible 
for BB and clopid therapy showed similar rates of associated hospital discharge therapy, 
with BB treatment rates of 90.90%, 92.43%, and 44.80% (p<.0001), and clopid treatment 
rates of 86.46%, 91.69%, and 37.91% (p<.0001). 
Conclusions Early treatment for NSTE ACS within the ﬁrst 24 hours in-hospital is 
associated with appropriate treatment on hospital discharge. Patients who did not receive 
appropriate early therapy were less likely to receive Guidelines-indicated medication 
when discharged from the hospital. This link between early treatment and discharge 
therapy may help to identify high-quality Guidelines-based care programs for NSTE ACS 
that can be expanded to other hospitals nationally.
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1001-214 Synergistic Effect of Stromelysin-1 (Matrix 
Metalloproteinase-3) Promoter 5a/6a Polymorphism 
With Smoking on the Onset of Acute Coronary 
Syndrome
Ping-Yen Liu, Jyh-Hong Chen, Yi-Heng Li, Hua-Li Wu, Guey-Yueh Shi, Division of 
Cardiology, Internal Medicine, National Cheng-Kung University Medical Center, Tainan, 
Taiwan,ROC
Background: Plaque rupture with thrombosis is well established as a critical factor in 
the pathogenesis of acute coronary syndrome (ACS). Stromelysin-1, also called matrix 
metalloproteinases-3 (MMP-3), can degrade extracellular matrix and are identiﬁed extensively 
in human coronary atheroslcerotic plaques, and may contribute to the weakening of the cap and 
subsequent rupture. In this case-control study, we analyzed the distribution of 5A mutation in the 
promoter region of stromelysin-1 gene and its association with the onset of ACS in Taiwan.
Methods: We studied 350 consecutive patients diagnosed as ACS with mean age of 
55.7±8.5 years (86% men) and 350 sex-matched control subjects (mean age 57.5±7.8 
years) of 5A/6A mutation at stromelysin-1 promoter by using polymerase chain reaction 
and direct DNA sequencing.
Results: The frequency of the 5A mutation (5A/5A + 5A/6A genotypes) was signiﬁcantly 
higher among ACS than the control group (29% vs. 18%, odds ratio [OR] 2.35, 95% 
conﬁdence interval [CI] 1.2 to 6.6, p=0.01). Multiple logistic regression analysis showed 
that the 5A allele polymorphism was an independent risk factor (OR 2.15, 95% CI 1.2 to 
5.3, p=0.01) as were as smoking (OR 3.77, 95% CI 1.5 to 5.4, p=0.001), diabetes mellitus 
(OR 3.51, 95% CI 1.4 to 6.3, p=0.003) and hypertension (OR 1.87, 95% CI 1.9 to 7.8, 
p=0.001) for the onset of ACS. Moreover, among patients who did not smoke, the 5A allele 
polymorphism was associated with an increase in the risk of ACS (OR 3.95, 95% CI 1.3 
to 9.3). Furthermore, smoking carriers of the stromelysin-1 5A allele polymorphism had a 
signiﬁcantly 9-fold increased risk of ACS (OR 8.75, 95% CI 2.5 to 15.5) when compared 
with non-smoking non-carriers.
Conclusion: There was a signiﬁcant association between the 5A/6A polymorphism in the 
promoter region of stromelysin-1 gene and ACS in Taiwan. Both the 5A/6A polymorphism 
of stromelysin-1 gene and smoking are independent risk factors for ACS population. A 
synergistic effect between these two risk factors for ACS had been shown in this study.
1001-244 Hepatic Injury late after the Fontan Circulation
Gruschen Veldtman, Theo Velissaris, Joseph Vettukattil, Richard Cope, Brian Stedman, 
Marcus Haw, Harry Milward-Sadler, Nick Cheron, David Breen, John Iredale, Barry 
Keeton, Anthony Salmon, Nigel Hacking, Wessex Adult Congenital Heart Unit, 
Southampton, United Kingdom
Background: The Fontan circulation is associated with obligatory central venous 
hypertension, depressed rest and exercise cardiac outputs, and previous prolonged 
exposure to hypoxia, all potential risk factors for liver injury. We sought to characterize 
patterns of hepatic injury in adults considered for Fontan conversion. 
Methods: Hospital records (1 Sept 2003 - present) were reviewed for all patients ≥ 16 
years, evaluated for Fontan conversion. 
Result: clinical characteristics of 7 patients (4 male) is shown in the table.
Diagnosis Age (yr)
Fontan 
duration 
(yr)
Fontan 
pressure 
(mmHg)
Hepatic 
wedge 
pressue 
(mmHg)
Cardiac 
index 
(L/m2/min)
Aortic 
saturation 
(%)
International 
normalized 
ratio off 
warfarin
Liver CT scan Liver biopsy
Tricuspid 
atresia 
(TA)
36 27 28 29 - 88 1.39
large varisces; 
macronodules; 
hypervascular 
nodules
cirrhosis
TA 17 13 12 12 1.5 99 1.2
macronodules; 
nutmeg 
transformation
ﬁbrosis 
and 
sinusoid 
ectasia
TA 18 14 15 15 1.9 97 - gallstones; reticular pattern
severe 
ﬁbrosis 
and 
sinusoidal 
ectasia
TA 23 17 9 10 2.7 99 1.2 reticular pattern
moderate 
ﬁbrosis 
and 
sinusoidal 
ectasia
TA 20 16 11 11 2.3 98 1.5 poor enhancement cirrhosis
Double inlet 
left ventricle 
(DILV)
16 13 19 20 3.3 99 1.2
macronodules; 
nutmeg 
transformation
ﬁbrosis
DILV 18 5 - - - 92 - gallstones; reticular pattern -
Conclusions. Despite apparent preservation of hepatocellular and synthetic liver function 
on routine bloodwork, striking morphological changes of congestion, ﬁbrosis and/or 
cirrhosis are uniformly present late after the Fontan operation. These changes do not 
correlate with resting hemodynamics. Hypervascular nodules may indicate arterialisation 
of hepatic ﬂow consequent to venous hypertension induced by sinusoidal block.. New 
surgical strategies are required to protect liver integrity in Fontan patients.
1001-264 Permanent Atrial Pacing Does Not Alter the Respiratory 
Parameters of Patients With Obstructive Sleep Apnoea 
Hypopnoea Syndrome
Emmanuel N. Simantirakis, Stavros I. Chrysostomakis, Sophia E. Schiza, Mary E. 
Marketou, Nick C. Klapsinos, Nikolaos S. Siafakas, Panos E. Vardas, Cardiology Dept., 
Heraklion University Hospital, Heraklion, Greece, Dept. of Pneumonology, Heraklion 
University Hospital, Heraklion, Greece
Introduction: The role of atrial overdrive pacing in obstructive sleep apnoea-hypopnoea 
syndrome (OSAHS) has recently been under investigation. Our aim was to compare the treatment 
effect of atrial overdrive pacing and continuous positive airway pressure (CPAP) treatment. 
We evaluated whether atrial overdrive pacing immediately improves the polysomnography 
respiratory parameters and maintains these effects over an extended period.
Methods: We prospectively evaluated 8 patients (6 men, aged 57±9 years) with moderate 
or severe OSAHS. In all patients a permanent pacemaker was implanted which was 
programmed to pace the atrium at a rate of 15 beats per minute faster than the mean 
nocturnal heart rate. All participants were randomized to continuous positive airway 
pressure (CPAP) or atrial pacing (AP) in a crossover design and underwent a full night 
polysomnography in the sleep laboratory, 7 days before implantation, 48 hours and 30 
days after AP or CPAP treatment in a random order.
Results: Please refer to Table 1.
Conclusions: There were no immediate or mid-term effects of AP on respiratory 
parameters, which were signiﬁcantly improved with CPAP treatment.
Table 1
Baseline CPAP - 48 hrs
AP - 
48 hrs
CPAP - 
30 days
AP - 
30 days
Heart rate (bpm) 63 ± 5 62 ± 7 76 ± 5 64 ± 4 76 ± 8
Apnoea/hypopnoea index (per hour) 49 ± 7 3,4 ± 0,8* 47 ± 6 2,8 ± 0,5* 46 ± 9
Arousal index (per hour) 55 ± 5 7,2 ± 1,6 57 ± 4 3.5 ± 0.9* 53 ± 7
Total sleep time (min) 333 ± 10 308 ± 7 322 ± 6 340 ± 11 347 ± 9
REM Sleep (% total sleep time) 8 ± 4 12 ± 3 11 ± 5 17 ± 4* 10 ± 3
Lowest desaturation 80 ± 5 90 ± 3* 80 ± 6 92 ± 2* 82 ± 4
* p < 0.05
1001-266 Alterations in Myocardial Adrenergic Innervation after 
Biventricular Pacing in Patients With Heart Failure and 
Left Bundle Branch Block
Emmanuel N. Simantirakis, Stavros I. Chrysostomakis, Nikolaos S. Karkavitsas, Sophia 
I. Koukouraki, Mary E. Marketou, Nick C. Klapsinos, Vassilis K. Prassopoulos, Panos 
E. Vardas, Cardiology Dept. Heraklion University Hospital, Heraklion, Greece, Dept. of 
Nuclear Medicine, Heraklion, Greece
Background: Cardiac resynchronization therapy (CRT) improves left ventricular 
performance and symptoms in heart failure patients with LBBB. Its effect on myocardial 
sympathetic activity, although known to be pathologically increased, has never been 
examined. We evaluated whether biventricular pacing beneﬁcially modulates the 
myocardial adrenergic innervation disturbances of the left ventricles in those patients.
Methods: We implanted a biventricular pacing system in 8 patients (5 males, 59±7 years) 
with LBBB and non-ischemic dilated cardiomyopathy, who were in sinus rhythm. All 
patients underwent planar and single-photon emission computed tomography (SPECT) 
myocardial imaging after intravenous infusion of 5mCi 123I-MIBG before and 6 months 
after the implantation. The heart to mediastinum (H/M) ratio at 10 minutes and 4 hours 
after drug infusion was calculated during the 123I-MIBG study in order to assess the 
global cardiac sympathetic activity, while the SPECT study investigated the regional 
distribution of adrenergic innervation. The percent washout rate (WR) was determined 
for the 4 hours period.
Results and conclusions: Six months after the initiation of biventricular pacing, the 
wash-out rate was signiﬁcantly reduced (16±3 % to 4±2 %, p=0.04) while regional 
adrenergic distribution improved signiﬁcantly with better uptake in the anterior and lateral 
wall (MIBG wall uptake score 3±1 % to 1±1 %, p=0.03). In conclusion, long-term CRT 
signiﬁcantly reduces myocardial adrenergic activity and more speciﬁcally, in the anterior 
and lateral regions of the left ventricle.
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1058-1 First Human Absorbable Metal Stent Implantation in 
Coronary Arteries
Raimund Erbel, Jorg Rodermann, Dirk Bose, Holger Eggebrecht, Thomas Konorza, 
Alexander Lind, Axel Schmermund, Michael Haude, University Clinic Essen, Essen, 
Germany
Despite technical and clinical success, stent technology can still be improved. 
Absorbable metal stents (AMS) may overcome some of the limitations. After successful 
experimental and clinical testing below the knee, the ﬁrst in man coronary implantation 
was performed.
Methods and Results: In de novo lesions, AMS were implanted in ﬁve patients on July 
30th, 2004. After predilatation with 10 mm 2.5 mm balloons, 3.0 x 15 mm AMS (Absorbable 
Metal Stent , Biotronik, Berlin, Germany) were delivered with 16 atm, 30 sec in two right 
coronary arteries, one left anterior descending, left circumﬂex and marginal branch. 
Postdilatation was performed in two cases. Vessel diameter increased from 1.1+/-0.1 to 
2.7+/-0.1 mm, diameter stenosis decreased from 66+/-9 to 12+/-1.6 %. The positioning of 
the stents had to be controlled by IVUS, because AMS stents consist of > 90% magnesium 
and are not imaged by X-ray. The reﬂected images were not different from bare metal 
stents except a more dense strut reﬂection of ultrasound (Fig.). Follow-up for 6 weeks was 
uneventful except for the 1st patient who developed atypical chest pain after 4 weeks with 
normal cardiac markers and stress ECG. Restenosis could be ruled out angiographically. 
IVUS demonstrated reduction in strut thickness and reﬂection intensity (Fig.).
Conclusions: The ﬁrst in man AMS stent implantations were very promising. The radial 
forces were comparable to bare metal stents. Absorption seems to proceed signiﬁcantly 
during the ﬁrst three weeks. 
1058-2 A Randomized Comparison of a Sirolimus With a 
Paclitaxel Eluting Stent For Coronary Revascularization: 
The SIRTAX Trial.
Stephan Windecker, Andrea Remondino, Peter Wenaweser, Mario Togni, Michael 
Billinger, David Tüller, Christian Seiler, Otto Hess, Franz Eberli, Willibald Maier, Marco 
Rofﬁ, Gabor Sütsch, Roberto Corti, Thomas Lüscher, Bernhard Meier, University 
Hospital Bern, Bern, Switzerland, University Hospital, Zurich, Switzerland
Background: Sirolimus (SES) and Paclitaxel (PES) eluting stents have been shown 
to reduce restenosis compared with bare metal stents. We performed a prospective, 
randomized trial to compare the clinical and angiographic efﬁcacy of SES with PES in 
patients (pts) undergoing percutaneous coronary revascularization (PCI).
Methods: A total of 1012 pts undergoing PCI were randomly assigned treatment with SES 
(n=503) and PES (n=509). Pts with >1 lesion (diameter stenosis >50%, reference vessel 
diameter >2.25 and <3.5 mm), which could be covered with >1 stents of 8-33 mm length were 
eligible for the study. Patients are followed for major adverse cardiac events (MACE) including 
death, myocardial infarction, and repeat revascularization. Angiographic measures of restenosis 
are in-lesion and in-segment late luminal loss measured 8 months after the index procedure.
Results: There were no differences between SES and PES treatment groups with respect 
to clinical and angiographic baseline characteristics. Procedural results and MACE at 30 
days are summarized in the table.
Conclusions: Coronary revascularization with SES and PES appears safe and effective. 
There are no differences between SES and PES with respect to procedural outcome and 
clinical events up to 30 days. The full data set of clinical and angiographic follow-up at 8 
months will be available at the time of the meeting. 
Total
(n=1012)
SES
(n=503)
PES
(n=509) P 
Age (years) 62 ± 11 62 ± 11 62 ± 12 0.86
Male sex (%) 77 76 78 0.35
Acute coronary syndrome (%) 51 51 52 0.85
Lesion success (%) 99.4 99.5 99.3 0.71
Device success (%) 98.6 98.1 99.1 0.23
30 Day MACE
Death (%) 0.6 0.2 1.0 0.32
Myocardial infarction
Q-wave (%)
Non-Q-wave (%)
2.2
0.6
1.6
2.2
0.8
1.4
2.2
0.4
1.8
0.99
0.46
0.55
Target lesion revascularization 1.8 2.2 1.4 0.290.39
Any major adverse cardiac event (%) 3.4 3.1 3.5 0.86
1058-5 CX3CR1 Receptor Mutant I249 Increases the Risk of 
Restenosis and Stent Thrombosis After Percutaneous 
Coronary Intervention
Alexander Niessner, Rodrig Marculescu, Heda Kvakan, Arvand Haschemi, Georg 
Endler, Gerlinde Zorn, Cornelia M. Weyand, Gerald Maurer, Christine Mannhalter, 
Johann Wojta, Oswald Wagner, Kurt Huber, Medical University of Vienna, Vienna, 
Austria, Wilhelminen-Hospital, Vienna, Austria
Background: The chemokine fractalkine (FKN) and its CX3CR1 receptor propagate 
leukocyte trafﬁcking into lesions of the arterial wall. Inﬂammatory cells play an important 
role in neointimal thickening after mechanical injury to arterial wall during stenting. FKN 
also regulates migration and proliferation of vascular smooth muscle cells, another 
mechanism pivotal to neointimal thickening. Moreover, FKN may increase the risk of 
thrombus formation. We assessed the hypothesis that the common and functionally 
important CX3CR1 receptor mutations M280 and I249 inﬂuence in-stent restenosis and 
stent thrombosis.
Methods: 365 patients undergoing coronary stenting were genotyped for M280 and 
I249. The primary endpoint was clinical in-stent restenosis, which was deﬁned by a new 
onset of symptoms or a positive stress test within 6 months related to angiographic in-
stent restenosis at the target lesion. A further endpoint was stent thrombosis deﬁned 
by an angiographically documented subacute closure of the stented segment. Finally, 
we investigated the role of CX3CR1 mutations in patients with recurrent (> 1) in-stent 
restenosis at the target lesion as conﬁrmed by repeat angiographies. Logistic regression 
was applied to assess the effect of CX3CR1 polymorphisms on deﬁned endpoints. We 
used multivariate analysis to adjust for sex, age and potentially confounding clinical and 
procedure-related variables.
Results: We observed clinical in-stent restenosis in 93 patients (25%), stent thrombosis 
in 7 patients (1.9%) and recurrent in-stent restenosis in 31 patients (9%). I249 was 
independently associated with an increased risk of in-stent restenosis (adjusted odds ratio 
[OR] 2, 95% conﬁdence interval [CI]: 1.1-3.4, P = 0.015). Furthermore, we found a harmful 
inﬂuence of I249 on stent thrombosis (OR 8.4, 95% CI: 1-71, P < 0.05) and recurrent in-
stent restenosis (OR 2.7, 95% CI: 1.3-5.9, P = 0.011). There was no signiﬁcant relation 
between M280 and any of the endpoints (P = ns).
Conclusion: The CX3CR1 receptor mutation I249 is associated with an increased risk of 
single and recurrent in-stent restenosis. Moreover, we found a substantially increased risk 
of stent thrombosis in patients with I249..
1058-6 Arterial Revascularization Therapies Study Part II of the 
Sirolimus-Eluting Stent in the Treatment of Patients With 
Multivessel De Novo Coronary Artery Lesions
Patrick Washington Serruys, Thoraxcenter, Erasmus Medical Center Rotterdam, 
Rotterdam, The Netherlands
Background: Arterial Revascularization Therapies Study (ARTS) was a randomized 
multicenter trial of 1205 patients with multivessel disease (MVD), comparing surgery 
(CABG, n=605) against stenting (PCI, n=600) on clinical outcome, costs and cost-
effectiveness. At one year, there was (1) no signiﬁcant difference in freedom from death, 
stroke or myocardial infarction between the two groups; (2) a 17% difference in repeat 
revascularization in favor of surgery; (3) lower costs (EUR 2,973) in favor of stenting at 
12 months. As the CYPHER® Sirolimus-eluting Stent has reduced restenosis rates vs. a 
bare metal stent, further evaluation of the CYPHER® Stent vs. the surgical arm of ARTS 
(ARTS I-CABG) is now warranted.
Methods: This is a multicenter, non-randomized, open-label, stratiﬁed trial with 607 
patients treated with CYPHER® Stents in 45 Pan-European centers. The primary 
objective is the effectiveness of the CYPHER® Stent versus ARTS I-CABG measured as 
survival free of Major Adverse Cardiac and Cerebrovascular Events (MACCE) at 1 year. 
Secondary objectives include MACCE at all follow-up visits (1M, 6M, 1Y, 3Y and 5Y), 
quality of life and cost effectiveness. 
Results: There were 2.5 diseased vessels in the ARTS II group vs. 2.3 in ARTS I-CABG. 
3.2 Lesions were treated in ARTS II vs. 2.5 anastomosed segments in the ARTS I-CABG. 
A post-procedure CK-MB release > 5 times the ULN was observed in 1.5% of ARTS II 
patients vs. 12.6% of ARTS I-CABG. ARTS II patients received a mean of 3.7 stents with 
an average total stented length of 72.5 mm. At 1 month, no MACCE occurred in 97.2% in 
ARTS II vs. 93.7% in ARTS I-CABG. (Sub)Acute stent thrombosis occurred in 5 patients 
(0.8%) in ARTS II vs. 17 patients (2.8%) in the ARTS I-PCI arm. 
Conclusions: At one month, overall MACCE and its itemized components are lower 
in ARTS II than in ARTS I-CABG despite more extensive disease and treatment. The 
primary endpoint of survival free of MACCE at one year will be presented at the meeting. 
Please note that this abstract is on behalf of all ARTS II investigators.
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1058-7 Efﬁcacy of Drug-Eluting Stents in the Treatment of 
Patients With In-Stent Restenosis and Diabetes Mellitus. 
Results of the Randomized ISAR-DESIRE Trial.
Jörg Hausleiter, Adnan Kastrati, Helmut Schühlen, Julinda Mehilli, Nicolas von 
Beckerath, Alban Dibra, Jürgen Pache, Josef Dirschinger, Albert Schömig, Deutsches 
Herzzentrum München, Munich, Germany, 1. Medizinische Klinik; Klinikum rechts der 
Isar, Munich, Germany
Background: Patients with in-stent restenosis (ISR) represent a subset with a very high 
risk for recurrence. Although drug-eluting stents (DES) are highly effective for primary 
prevention of restenosis, their value for patients with ISR is not known. In ISAR-DESIRE 
(Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent 
Restenosis) we demonstrated that a strategy based on DES is superior to plain balloon 
angioplasty (PTCA) for the reduction of recurrent restenosis in patients with ISR. The 
objective of this pre-speciﬁed subgroup analysis was to assess the impact of DES in the 
treatment of patients with ISR and diabetes mellitus (DM).
Methods: In ISAR-DESIRE a total of 300 patients with ISR were randomized to receive 
sirolimus-eluting (Cypher) or paclitaxal-eluting (Taxus) stents or PTCA. The primary study 
endpoint was the binary rate of angiographic restenosis; repeat angiography at 6 months 
was performed in 92% of patients.
Results: 28% of the entire study population presented with DM. The Figure presents the 
angiographic restenosis rates for patients with and without DM. 
Conclusions: In patients with ISR, a strategy based on DES (Cypher or Taxus) is superior 
to PTCA for the reduction of recurrent restenosis. This strategy is similarly efﬁcacious in 
the high-risk subgroup of patients with ISR and DM. The use of sirolimus-eluting stents 
has the potential of a greater beneﬁt than the use of paclitaxel-eluting stents in patients 
with and without DM.
1058-54 Protective Effect of Beta blocker Therapy in Chronic 
Severe Mitral Regurgitation Patients With Normal 
Ejection Fraction
Padmini Varadarajan, David Appel, Nirav Joshi, Lavanya Duvvuri, Ramdas G. Pai, Loma 
Linda University Medical Center, Loma Linda, CA, USC-Keck School of Medicine, Los 
Angeles, CA
Background: Chronic severe mitral regurgitation (MR) causes LV volume overload and 
neuroendocrine activation despite normal EF. However, it is not known if modulating 
the neuroendocrine system in these patients is helpful. We sought to determine if beta 
blockers have any beneﬁcial effects in these patients.
Methods: Patients were searched from our echocardiographic database. Full chart 
reviews were conducted for clinical and pharmacological data. Mortality data was obtained 
from the National Death Index.
Results: A total of 869 patients had severe MR and normal LVEF. Patient characteristics: 
Age 68+17 years, 44% men, EF 66+7%, diabetes mellitus in 19%, hypertension in 65%, 
coronary artery disease (CAD) in 39%. Mitral valve surgery was performed in 44% and 
42% were on a beta blocker. Use of beta blocker was associated with a signiﬁcantly 
reduced mortality hazard (p=0.002) which remained unchanged after adjusting for age, 
gender, EF, CAD, diabetes, hypertension and valve surgery. The independent beneﬁcial 
effects of beta blockers were seen in patients with CAD and no CAD as well as patients 
managed both surgically and conservatively.
Conclusions: Use of beta blocker therapy is associated with a signiﬁcant, independent 
survival beneﬁt in chronic severe MR patients with normal EF. This beneﬁt is seen in 
patients with or without CAD and both medically and surgically managed patients. These 
protective effects of beta blockers in severe MR warrant further investigations. 
 
 
 
1058-58 Is Microalbuminuria An Indicator Of Myocardial 
Dysfunction In Diabetic Patients? A Study With Doppler 
Strain And Strain Rate Imaging
Chi Young Shim, Seong-Hoon Choi, Won-Ho Kim, Jin-Bae Kim, Ji-Young Kim, Sungha 
Park, Eui-Young Choi, Seok-Min Kang, Bong-Soo Cha, Hyun-Chul Lee, Jong-Won 
Ha, Se-Joong Rim, Namsik Chung, Yonsei Cardiovascular Center and Cardiovascular 
Research Institute, Seoul, South Korea
Background: The aim of this study was to examine the relationship of albuminuria to 
myocardial dysfunction in diabetes patients using strain and strain rate imaging. 
Methods: Fifty-two pts (37 with type II DM and HTN, 15 with HTN only, mean age: 
56.6±11.3) were enrolled prospectively. All pts had normal EF. Pts with LVH or CAD were 
excluded. On albuminuria status, diabetes pts were divided into 3 groups.: Group II = no 
albuminuria( n=15, <30 mg/d); Group III = microalbuminuria ( n=12, 30 to 300 mg/d); and 
Group IV = macroalbuminuria ( n=10, >300 mg/d). Fifteen pts with HTN only served as a 
control(Group I). Conventional 2D and Doppler echo were done. Peak strain,peak systolic 
and peak diastolic SR of six walls in apical views were measured and averaged. 
Results: LVEF, LA volume index, LV mass, DT, E, A, E’, S’ velocity were not different 
among 4 groups. Peak strains were signiﬁcantly lower in group III(19.6±1.2%, p=0.002) 
and group IV (17.4±1.9%, p<0.001) than group I(23.2±1.9%). Absolute value of peak 
systolic SR was lower in group III(-1.44±0.27 s-1, p=0.033) and group IV(-1.11±1.19 s-1, 
p<0.001) than group I(-1.58±0.30 s-1). The value of peak diastolic SR was lower in group 
IV (1.83±0.60 s-1, p=0.014) than group I (2.32±0.29 s-1). 
Conclusions: In diabetes pts without overt heart disease, albuminuria is associated with 
myocardial dysfunction assessed by strain and strain rate imaging. Unlike, conventional 
2D and Doppler parameters, strain and SR imaging detected LV systolic and diastolic 
dysfunction in DM pts..
Echocardiographic characteristics in each groups 
Group I
(n=15)
Group II
(n=15)
Group III
(n=12)
Group IV
(n=10)
E velocity
(cm/s) 0.6±0.1 0.6±0.1 0.7±0.2 0.7±0.2
A velocity
(cm/s) 0.7±0.2 0.7±0.1 0.8±0.2 0.8±0.2
Deceleration Time(msec) 211±32 216±39 199±38 200±28
E’ velocity
(cm/s) 5.5±1.1 6.6±1.4 5.9±1.4 6.0±2.0
S’ velocity
(cm/s) 6.8±0.8 6.7±1.1 6.3±0.5 6.2±0.8
Peak Strain(%) 23.2±1.9 21.3±3.3* 19.6±1.2* 17.4±1.9*
Peak systolic strain rate(s-1) -1.58±0.30 -1.50±0.29 -1.44±0.27* -1.11±1.19*
Peak diastolic strain rate(s-1) 2.32±0.29 2.46±0.77 2.09±0.33 1.83±0.60*
1058-61 Does Exercise Intolerance in Metabolic Syndrome 
reﬂect Subclinical Myocardial Dysfunction
Chiew Wong, Trisha O’Moore-Sullivan, Rodel Leano, Thomas H. Marwick, University of 
Queensland, Brisbane, Australia
Recent work has suggested subclinical LV dysfunction to occur in pts with type II diabetes. We 
sought whether the same phenomenon could be identiﬁed in the wider metabolic syndrome 
(MS), and whether this could account for impaired exercise capacity in these pts.
Methods: Quantitative assessment of myocardial function were performed in 393 
subjects with signiﬁcant risk factors but no cardiovascular disease and a negative stress 
echo. Myocardial function was assessed by the average of strain rate [SR], strain [�] in all 
myocardial segts, and regional myocardial systolic velocity [sm], diastolic velocity [em] . 
Exercise capacity was measured by VO2 max.
Results: There was signiﬁcant and incremental variation in the subclinical changes in the 
myocardial function LV systolic (sm, global strain and strain rate) and diastolic function 
(em) according to the number of components of MS (p<0.001, see Table 1). The reduction 
of em with MS was independent of LV mass index but was potentiated by LV mass (test 
of interaction, p<0.05). Myocardial changes were correlated with visceral obesity (r=0.38, 
p<0.001) and DM (r=0.24, p<0.001) more than with other features of MS. LV measures of 
strain rate and em were independent predictors for exercise capacity.
Conclusion: Subclinical myocardial dysfunction is associated with MS in pts without 
overt cardiovascular disease, independent of LV hypertrophy and is related to reduced 
functional capacity.
Table 1 relationship between number of components of metabolic syndrome and 
measures of LV function
Myocardial function /Vo2 max. components of metabolic syndrome
0 (n=35) 1 (n=84) 2 (n=116) 3 (n=88) 4 (59) 5 (10) Sig.
systolic Sm (cm/s) 6.5+/-2.0 5.8+/-1.7 5.2+/-1.6 5.1+/-1.6 5.0+/-1.4 4.4+/-1.4 <0.001
SR (s-1 ) -1.6+/-0.3 -1.5+/-0.3 -1.4+/-0.3 -1.4+/-0.3 -1.3+/-0.2 -1.2+/-0.1 0.002
� (%) -24+/-5 -23+/-4 -22+/-4 -21+/-4 -21+/-3 -18+/-2 <0.001
diastolic em (cm/s) 8.9+/-2.7 6.8+/-2.3 5.7+/-2.2 5.4+/-1.9 5.0+/-1.6 4.0+/-1.5 <0.001
Vo2 max. (ml/kg/min) 35+/-6 27+/-9 25+/-10 24+/-9 20+/-6 20+/-3 <0.001
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1058-62 Meta-Analysis of Comparative Diagnostic Performance 
of Magnetic Resonance Imaging and Multi-Slice 
Computed Tomography for Non-Invasive Coronary 
Angiography
Joanne D. Schuijf, Jeroen J. Bax, Leslee J. Shaw, Albert de Roos, Ernst E. van der Wall, 
William Wijns, Leiden University Medical Center, Leiden, The Netherlands
Background: Magnetic Resonance Imaging (MRI) and Multi-Slice Computed Tomography 
(MSCT) have emerged as potential non-invasive coronary imaging techniques. The 
objective of the present study was to clarify the current accuracy of both modalities in 
the detection of signiﬁcant coronary artery lesions by means of a comprehensive meta-
analysis of the presently available literature.
Methods: A total of 50 studies on the detection of coronary artery stenoses and 
comparative to invasive coronary angiography were identiﬁed by means of a MEDLINE 
search. Weighted sensitivities, speciﬁcities, predictive values, all with 95% conﬁdence 
intervals (CIs), and summary odds ratios were calculated for both techniques. In addition, 
the relationship between diagnostic speciﬁcity and disease prevalence was determined 
using meta-regression analysis.
Results: A comparison of sensitivity revealed signiﬁcantly higher accuracy for MSCT 
(weighted average: 82%, 95% CI: 79%-90%) as compared with MRI (weighted average: 
75%, 95% CI: 60%-84%, p=0.029, Monte Carlo simulation [n=10,000]). A signiﬁcant 
difference was also observed for the weighted speciﬁcity, which was 95% (95% CI: 94%-
96%) for MSCT and 87% (95% CI: 85%-88%) for MRI (p<0.05). A signiﬁcantly higher 
odds ratio (11.5-fold) for the presence of signiﬁcant stenosis was observed for MSCT 
as compared to MRI (6.6-fold) (p<0.0001). Linear-regression analysis revealed a better 
speciﬁcity for MSCT versus MRI in lower disease prevalence populations (p=0.022).
Conclusion: The results of the current meta-analysis indicate that MSCT has currently a 
substantial advantage over MRI. Thus, MSCT may be considered the technique of choice 
to non-invasively evaluate coronary artery anatomy.
1058-113 Pravastatin-Induced Decrease in Monocyte Count Is an 
Independent Predictor of Coronary Plaque Regression: 
A Three-Dimensional Intravascular Ultrasound Study
Shigemasa Tani, Ikuyoshi Watanabe, Takeo Anazawa, Ken Nagao, Hirofumi Kawamata, 
Eizo Tachibana, Kazutoshi Ishikawa, Kuyotaka Furukawa, Motoyuki Onikura, Toshio 
Kushiro, Katsuo Kanmatsuse, Department of Cardiology, Surugadai Nihon University 
Hospital, Tokyo, Japan, Department of Emergency and Critical Care Medicine, Nihon 
University School of Medicine, Tokyo, Japan
Background: Prospective epidemiological studies have shown an association between 
leukocyte count and coronary heart disease, and leukocyte count has been recognized as a 
predictor of ischemic heart events (Circulation. 2003;107:499). The present study investigated 
how the anti-inﬂammatory effects of statins inﬂuence coronary plaque regression.
Methods and Results: In a six-month prospective study, 75 patients with stable 
angina pectoris were randomly assigned to either a pravastatin-treatment group (n=50) 
or a control group (n=25). Three-dimensional intravascular ultrasound revealed that the 
coronary plaque volume in matched coronary segments decreased signiﬁcantly by 19.2% 
in the pravastatin group. The high-sensitive (hs) CRP level and total leukocyte count also 
decreased signiﬁcantly by 72.4 and 8.9%, respectively, while no signiﬁcant changes in 
the levels of soluble cell adhesion molecules were observed. No signiﬁcant changes in 
the aforementioned variables occurred in the control group. In the pravastatin group, the 
percent-change in plaque volume was correlated with changes in the total leukocyte 
(r=0.38, p=0.008), neutrophil (r=0.38, p=0.008), and monocyte (r=0.45, p=0.001) counts 
but not with changes in the lymphocte (r=0.21, p=0.16), eosinophil (r=0.12, p=0.40), or 
basophil (r=0.07, p=0.66) counts or with the levels of total cholesterol (r=-0.05, p=0.76), 
low-density lipoprotein cholesterol (r=-0.11, p=0.47), or hs-CRP (r=0.21, p=0.24). 
Furthermore, reduced monocyte count was the most powerful independent predictor of 
a decrease in coronary plaque volume, according to a stepwise multivariate regression 
analysis of the total leukocyte, neutrophil, and monocyte counts with conventional risk 
factors and medications as covariates.
Conclusions: Six months of pravastatin therapy reduced coronary plaque volume and 
further induced a corresponding decrease in the leukocyte count. A reduction in the 
monocyte count as a result of the non-lipid-lowering effects of pravastatin may be a novel 
marker of coronary atherosclerosis regression.
1058-114 Phenotypic Assessment of Endothelial Microparticles 
in Patients With Heart Failure and After Heart 
Transplantation: A Switch From Cell Activation to 
Apoptosis
Santiago Garcia, Fredy del Carpio, Julio A. Chirinos, Jorge Lascano, Javier Jimenez, Roque 
Arteaga, Jose Osorio, Mariana Canoniero, Yeon Ahn, University of Miami, Miami, FL
Background: Endothelial cells (EC) release phenotypically and quantitatively distinct 
endothelial microparticles (EMPs) in activation and apoptosis. The antigenic phenotypes 
of EMPs tend to reﬂect those of endothelial cells. In activation, for instance, EC release 
EMPs that express inducible markers (e.g. CD62E), whereas in apoptosis EMP’s carry 
constitutive markers (e.g. CD31). Therefore, phenotypic assessment of EMPs can provide 
useful information reﬂecting the nature of endothelial injury. We tested the hypothesis that 
heart transplantation (HT) modiﬁes the pattern of endothelial injury seen in patients with 
congestive heart failure (CHF).
Methods: Flow cytometry was used to measure EMPs identiﬁed by CD62E (EMP62E) 
and CD31 (EMP31) in 23 patients with advanced CHF, in 23 HT recipients without 
evidence of infection or allograft rejection and in 23 healthy subjects. The EMP62E/ 
EMP31 ratio was used as a marker of endothelial cell apoptosis (low ratio) or activation 
(high ratio). Results were analyzed using the Wilcoxon test (Mann-Whitney) or t test for 
unpaired data as appropriate.
Results: Levels of endothelial microparticles expressing CD62E+ were signiﬁcantly 
different among study groups (ANOVA p< 0.0001). Heart failure patients were found 
to have signiﬁcantly higher levels of EMP 62E+ (577.0±2.29 counts/µL) than controls 
(192.35±1.41 counts/µL) and post-transplant patients (152.12±3.27 counts/µL). Levels 
of endothelial microparticles expressing CD31+ were signiﬁcantly different among 
study groups (ANOVA p= 0.001). Heart failure patients had signiﬁcantly higher levels 
(1526.28±3.82 counts/µL) than controls (395.62±2.45 counts/µL). Levels of EMP 31+ 
remained elevated after heart transplant (935.91±3 counts/µL) and demonstrated no 
signiﬁcant differences with heart failure patients.
The EMP62/EMP31 ratio was signiﬁcantly different between the groups (ANOVA p=0.01). 
Post-transplant patients had signiﬁcantly lower ratios (0.16) than CHF patients (0.38) and 
controls (0.49). No signiﬁcant differences were found between CHF patients and controls.
Conclusions: Patients with congestive heart failure have enhanced endothelial cell 
activity. Cardiac transplantation improves endothelial cell activation associated with heart 
failure with little impact on endothelial cell apoptosis.
1058-115 Pathophysiological Role of Endothelin-1 on High 
Altitude Induced Pulmonary Hypertension. Effects Of 
Bosentan Administration
Iacopo Bertolozzi, Valentina Scheggi, Ilaria Cecioni, Simone Vanni, Francesco Burberi, 
Isabella Riva, Gianluca Caldara, Giuseppe Mancia, Gianfranco Gensini, Pietro A. 
Modesti, Gianfranco Parati, Clinica Medica e Cardiologia, University of Florence, 
Florence, Italy, University of Milano-Bicocca and S.Luca Hospital, Istituto Auxologico 
Italiano, Milan, Italy
Background: High altitude pulmonary edema (HAPE) is a life threatening complication 
with an estimated prevalence ranging from 1% in the mountaineering population, living at > 
2500m, to 10% in subjects examined after rapid ascent (within 24hours) to 4559m. Although 
the mechanisms responsible for HAPE are not yet fully understood, in HAPE-prone subjects 
were found larger increases in both endothelin(ET)-1 plasma levels and systolic pulmonary 
artery pressure (sPAP) than in individuals who did not develop HAPE.
The aim of the study was to deﬁne the pathophysiological role of ET-1 on high altitude 
(HA) induced pulmonary hypertension, and to evaluate the possible beneﬁt associated 
with pharmacological blockade of ET-1 receptors.
Methods: In a double blind placebo controlled study we randomly assigned 16 healthy adult 
volunteers (3 females and 13 males, age 40±11 years), to receive placebo or bosentan 
(62,5 mg for 1 day and 125 mg for the following 2 days) both at sea level (SL) and after 
rapid ascent to HA (Queen Margherita Hut, Italy, 4559 m). Non invasive measurements of 
oxygen saturation (Nihon-Kohden 1523, Japan) and sPAP (Echocardiography, Caris Plus 
Esaote) were performed daily by the same physician both at SL and at HA.
Results: At SL baseline ofﬁce blood pressure (115±10/70±5 mmHg), sPAP and oxygen 
saturation were not modiﬁed by bosentan (ns vs placebo). Oxygen saturation at HA was 
markedly reduced vs SL on the ﬁrst day (74±7% vs 99±1%, p< 001). This was associated 
with a parallel increase in sPAP by 115% (from 16±2 to 34±7 mmHg), while systemic blood 
pressure was 126±13/80±9 mmHg (p<0.05 vs SL). Bosentan did not signiﬁcantly modify 
systemic blood pressure (ns vs placebo) but induced a signiﬁcant reduction of sPAP and 
a mild increase in oxygen saturation vs placebo after one day of treatment (respectively 
21±7 vs 31±11 mmHg, p<0.03 and 81±6% vs 74±12%, p=0.06). At the third day sPAP 
and oxygen saturation were comparable in the two groups (19±8 vs 22±6, ns and 81±8 
vs 81±4, ns).
Conclusion: Bosentan administration effectively reduces sPAP during acute exposure to 
HA. This suggests a pathophysiological role of ET-1 on HA induced pulmonary hypertension, 
and its possible involvement in the pathogenesis of HAPE.
1058-116 Hemodynamic Effects of Sildenaﬁl Citrate in Patients 
With Pulmonary Arterial Hypertension: Results of a 
Multicenter, International, Randomized, Double Blind, 
Placebo-Controlled Trial
Robyn J. Barst, on behalf of the Sildenaﬁl 1140 Study Team, Columbia University 
College of Physicians & Surgeons, New York, NY
Background: Sildenaﬁl citrate inhibits phosphodiesterase type 5, an enzyme that 
metabolizes cyclic guanosine monophosphate (cGMP), thereby enhancing cGMP-
mediated relaxation of vascular smooth muscle, including that of the pulmonary 
vasculature. We report the hemodynamic effects of chronic oral sildenaﬁl therapy in 
patients with pulmonary arterial hypertension (PAH).
Methods: In this 12-week, double-blind, placebo-controlled study, 278 patients with PAH 
(idiopathic or associated with connective-tissue disease or following surgical repair of 
congenital heart defects) were randomized to placebo or sildenaﬁl (20, 40, or 80 mg) 
3 times daily. Six-minute walk distance and hemodynamic measurements were made 
at baseline and at week 12. Week-12 assessments were performed at trough plasma 
concentrations of study medication, ie, at least 4 hours postdose.
Results: Sildenaﬁl signiﬁcantly decreased mean pulmonary artery pressure and 
pulmonary vascular resistance and increased cardiac output and mixed venous oxygen 
saturation (table). These hemodynamic improvements were accompanied by signiﬁcant 
improvements in exercise capacity (45-50 meter treatment effect across all 3 doses in 
6-minute walk distance, P<0.001). 
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Mean (95% Conﬁdence Interval) Change From Baseline to Week 12 in Hemodynamic Parameters
Parameter
Treatment Group
Placebo
(n=65)*
Sildenaﬁl 20 mg 
(n=65)*
Sildenaﬁl 40 mg 
(n=63)*
Sildenaﬁl 80 mg 
(n=65)*
Mean pulmonary artery pressure 
(mmHg) 0.6 (-0.8, 2.0) -2.1 (-4.3, 0.0)
+ -2.6 (-4.4, -0.9)+ -4.7 (-6.7, -2.8)+
Pulmonary vascular resistance 
(dyn·s/cm5) 49 (-54, 153) -122 (-217, -27)
+ -143 (-218, -69)+ -261 (-365, -157)+
Cardiac output (L/min) -0.1 (-0.4, 0.2) 0.4 (0.1, 0.7)+ 0.4 (0.1, 0.8)+ 0.7 (0.4, 1.0)+
Heart rate (beats/min) -1.3 (-4.1, 1.4) -3.7 (-5.9, -1.4) -3.3 (-5.5, -1.0) -4.7 (-7.3, -2.2)
Systemic vascular resistance 
(dyn·s/cm5) -78 (-197, 41) -167 (-307, -26) -258 (-401, -114)
-323 (-451, 
-195)+
Mixed venous oxygen saturation 
(%) -2.4 (-4.7, -0.2) 1.1 (-0.5, 2.7)
+ 2.2 (-0.2, 4.6)+ 2.0 (-0.2, 4.1)+
Right atrial pressure (mmHg) 0.3 (-0.9, 1.5) -0.8 (-1.9, 0.3) -1.1 (-2.4, 0.2) -1.0 (-2.1, 0.1)
Pulmonary capillary wedge 
pressure (mmHg) -0.4 (-1.3, 0.5) -0.2 (-1.6, 1.1) 0.2 (-0.7, 1.2) 0.2 (-0.9, 1.2)
Mean systemic arterial pressure 
(mmHg)  -3.1 (-6.2, -0.1) -2.6 (-5.1, -0.1) -0.9 (-3.8, 1.9) -4.9 (7.8, -2.0)
*The number of patients per treatment group varied slightly for each parameter due to missing assessments.
+P<0.05. P values for the comparison between placebo and each sildenaﬁl dose group for each parameter, not 
adjusted for multiple testing.
Conclusion: Sildenaﬁl treatment in patients with PAH improved hemodynamic 
parameters, which was associated with an increase in exercise capacity.
1058-117 ACE Inhibitors or Angiotensin Receptor Blockers for 
Prevention of Type 2 Diabetes
Hussam Abuissa, James O’Keefe, Jr., David Bell, Phil Jones, Steven Marso, Mid 
America Heart Institute, Kansas City, MO, University of Alabama, Birmingham, AL
Background: Type 2 diabetes mellitus is a public health problem of epidemic proportions 
and its prevalence is on the rise. The typical American born today has a one in three 
chance of developing type 2 diabetes. This diagnosis is associated with an adverse 
cardiovascular prognosis and is considered the risk equivalent of established coronary 
disease. Many risk factors, including the metabolic syndrome, have been implicated in 
its development. Even in high-risk individuals, type 2 diabetes is a preventable disease. 
However, the exact role of angiotensin converting enzyme (ACE) inhibitors or angiotensin 
receptor blockers (ARBs) in diabetes prevention has not been fully elucidated yet.
Methods: We conducted a meta-analysis, using a random effects model, of eight 
randomized controlled clinical trials of ACE inhibitors or ARBs involving 99,497 patients to 
study the efﬁcacy of these medications in diabetes prevention. Estimates were computed 
over all studies and separately for ACE inhibitor and ARB trials.
Results: ACE inhibitors and ARBs were associated with reductions in the incidence of newly 
diagnosed diabetes by 35% and 23% respectively and 28% in the combined pooled analysis.
Conclusion: The use of an ACE inhibitor or ARB should be considered in patients with 
conditions such as the metabolic syndrome, hypertension, impaired fasting glucose, family 
history of diabetes, obesity, congestive heart failure or other risks for the development of 
type 2 diabetes..
1058-151 WITHDRAWN
1058-152 Combined Therapy With Peroxisome Proliferator-
Activated Receptor α Agonist and Carnitine 
Supplementation Rescues the Detrimental 
Cardiomyopathy With Fatty Acid Oxidation Disorder due 
to Systemic Carnitine Deﬁciency
Toru Asai, Ryotaro Takahashi, Hisashi Murakami, Ryuichiro Murakami, Yasushi 
Numaguchi, Hideo Matsui, Kenji Okumura, Toyoaki Murohara, Nagoya University 
Graduate School of Medicine, Nagoya, Japan
Background: Systemic carnitine deﬁciency (SCD) develops hypertrophic cardiomyopathy 
due to impaired fatty acid oxidation. We investigated the effect of combined therapy with 
fenoﬁbrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, and carnitine 
supplementation on the myopathic heart in juvenile visceral steatosis (JVS) mouse, a 
genetic model of SCD.
Methods: Both wild-type and JVS mice were fed a normal chow, a 0.1% carnitine/kg 
containing chow (CA), or a 0.1% carnitine/kg and 0.2% fenoﬁbrate/kg containing chow 
(CA+FE) from 4 weeks of age.
Results: At 8 weeks of age, the ventricular hypertrophy in JVS mice was more attenuated 
by CA+FE than by CA alone (Table). CA+FE prevented the progressive deterioration of left 
ventricular fractional shortening in JVS mice. CA+FE markedly reduced the accumulation 
of triglycerides and increased the low ATP content to control levels in the hearts of JVS 
mice. In JVS mice, the fatty acid composition of myocardial 1,2-diacylglycerol showed 
elevation of C18:1n-7,9 and C18:2n-6 fatty acids compared with that in wild-type mice 
(both p<0.01); CA+FE reduced these fatty acids (p<0.01 and p<0.05 vs. JVS mice, 
respectively). CA+FE also inhibited the membrane translocation of cardiac protein kinase 
C �2 in JVS mice.
Conclusion: Combined therapy with PPARα agonist and carnitine supplementation may 
rescue the detrimental cardiomyopathy in SCD by improving energy and lipid metabolism 
and by modulating the 1,2-diacylglycerol-protein kinase C pathway.
Ventricular 
weight-to-body 
weight ratio 
(8wk) (mg/g)
LVFS (8wk) 
(%)
LVFS (16wk) 
(%)
Myocardial ATP 
content (8wk) 
(nmol/g)
Myocardial 
triglyceride 
levels (8wk) 
(µg/mg dry 
ventricular wt)
Membrane-to-
cytosol ratio of 
cardiac PKCβ2 
(8wk)
Wild-type 3.8±0.1 54.5±1.8 53.4±1.0 2.42±0.21 6.2±0.4 0.45±0.05
JVS 7.0±0.1* 39.2±0.8* 23.5±2.9* 1.13±0.19* 92.5±7.1* 0.95±0.05*
JVS+CA 6.0±0.1*,† 46.0±0.3*,† 38.3±0.7*,† 1.51±0.20* 48.3±2.6*,† 0.84±0.06*
JVS+(CA+FE) 5.2±0.1*,†,‡ 50.4±0.8†,§ 48.4±0.8†,‡ 2.33±0.13†,§ 15.3±0.8†,‡ 0.55±0.06†,‡
Mean±SEM, n=8, *p<0.01 vs. Wild-type, †p<0.01 vs. JVS, ‡p<0.01 vs. JVS+CA, §p<0.05 vs. JVS+CA.
1058-153 Acute Changes in Left Ventricular Function Induced by 
Percutaneous Transluminal Septal Alcohol Ablation in 
Patients With Hypertrophic Cardiomyopathy Assessed 
by Pressure-Volume Loops
Marco Valgimigli, Paul Steendijk, Elena Biagini, Emilie Onderwater, Chris Van der Lee, 
Folkert Ten Cate, Patrick Washington Serruys, Department of Interventional Cardiology, 
Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands, Department of Cardiology, 
Leiden, The Netherlands
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) has 
been shown to be effective in relieving outﬂow obstruction and improving symptoms in 
hypertrophic cardiomyopathy (HCM). However, the acute hemodynamic changes and 
their relationship with the degree of obstruction resolution are poorly understood. The 
effects of PTSMA on left ventricular (LV) diastolic function were speciﬁcally investigated.
Methods: In 11 consecutive HCM patients (mean age: 62±14, 4 females) undergoing 
PTSMA, LV end-systolic and end-diastolic volumes and pressures (ESV, EDV, ml, EDP, 
ESP, mmHg), maximal and negative dP/dt (mmHg/s), ejection fraction (EF, %), stroke 
work (SW, mmHg.ml), relaxation time constant (Tau, ms) and pressure-half time (PHT, 
ms) were collected through LV pressure-volume (PV) loops obtained by conductance 
catheter.
Results: Ethanol (2.0±0.6 cc) was injected in 1.1±0.3 septal branches/patient. The LV 
outﬂow tract obstruction reduced from 76±42 to 11±17 mmHg, (p<0.001). The effects on 
LV function are shown in the table.
The decrease of ESP the procedure correlated to the degree of EDP and PHT reduction 
(r=0.94, r=0.64)
Conclusion: PTSMA acutely reduced systolic function evidenced by the increase in end-
systolic volume and reduced ejection fraction. The procedure promptly improved diastolic 
function as indicated by the reduced end-diastolic pressure and relaxation times. The 
improvements in diastolic function correlated with the reduction in outﬂow tract gradient.
*<p0.05 ESV EF +dP/dt -dP/dt ESP EDP SW Tau PHT
Prior 35 74 1563 -1681 163 24 9274 78 43
After 49* 59* 1434 -1346* 124* 16* 7304* 61 34*
1058-154 Regulatory Mutations in Transforming Growth Factor-
β3 Gene Cause Arrhythmogenic Right Ventricular 
Cardiomyopathy Type 1
Alessandra Rampazzo, Giorgia Beffagna, Gianluca Occhi, Andrea Nava, Libero Vitiello, 
Andrea P. Ditadi, Cristina Basso, Barbara Bauce, Gianni Carraro, Gaetano Thiene, 
Jeffrey A. Towbin, Gian Antonio Danieli, University of Padua, Padua, Italy, Baylor College 
of Medicine, Houston, TX
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically 
heterogeneous disorder characterized by ﬁbro-fatty replacement of the right ventricular 
myocardium, associated with high risk of sudden death. Among eight dominant forms, 
two disease-genes have been identiﬁed so far. The identiﬁcation of the gene involved in 
ARVD1 has been elusive ever since its locus was mapped to chromosome 14q24.3.
Methods: Mutation screening of the transforming growth factor-beta3 (TGFβ3) gene 
was performed by direct sequencing of genomic DNA of one index case belonging to 
an ARVD1 family including 38 members in four generations. Investigation was extended 
to 30 unrelated ARVC patients by denaturing high-performance liquid chromatography 
(DHPLC). In order to test whether the UTRs mutations could affect the expression levels 
of TGFβ3 gene, we prepared four different plasmid constructs in which luciferase reporter 
gene was put under control of either wild-type or mutant regions. These plasmids were 
then used to perform transient transfections into the murine myoblast cell line C2C12.
Results: We detected a nucleotide substitution (c.-36G>A) in 5’ UTR of TGFβ3 gene, 
invariably associated with the typical ARVC clinical phenotype in the affected family 
members, according to the established diagnostic criteria. Investigation extended to 30 
unrelated ARVC patients led to the identiﬁcation of an additional mutation (c.1723C>T) in 
3’ UTR of one proband whose brother died suddenly and resulted affected with ARVC at 
autopsy. Neither nucleotide change was found in 300 control subjects. In vitro expression 
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assays with constructs containing these mutations showed that mutated UTRs were 
twofold more active than wild-types.
Conclusions: Finding TGFβ3 regulatory mutations associated with ARVD is interesting, 
since this gene is involved in ﬁbrosis induction and cell-cell adhesion regulation. The 
identiﬁcation of a novel ARVC gene will increase the power of the genetic screening for 
early diagnosis of asymptomatic carriers among relatives of ARVC patients.
1058-155 The Impact Of Hypogammaglobulinemia On Infections 
In Patients With Ventricular Assist Devices
Tehmeena Shah, Mohamad H. Yamani, Ann McNeill, Robin K. Avery, Steven Mawhorter, 
Susan Saber, Daniel J. Cook, Tiffany Buda, M. Yeager, Robert E. Hobbs, David Taylor, 
James B. Young, Nicholas Smedira, Randall C. Starling, THE CLEVELAND CLINIC 
FOUNDATION, CLEVELAND, OH
Background: Infection is a major comorbidity following ventricular assist device (VAD) 
placement. Defects in cellular immunity have been reported following VAD placement. 
However, quantitative IgG level determination and the impact of hypogammaglobulinemia 
(HGG) on infections following VAD implantation has not been evaluated before.
Methods: Between April 1999 and February 2004, a total of 76 patients (mean age= 53 
+/- 10 years) underwent VAD implantation (64 Heartmate, 2 Novacor, 2 DeBakey, 2 Jarvik 
and 6 Thoratec) and had IgG level determined. Hypogammaglobulinemia was deﬁned as 
IgG level below 700mg/dl. Patients were divided into 2 groups, the control group (n=56) 
with normal IgG (>700mg/dl) and the HGG group (n=20) with low IgG (<700mg/dl). The 
incidence of bacteremia, device related infections and all other infections were evaluated 
during the VAD course. All patients survived to transplantation. Infection outcome following 
transplantation was also analyzed in relation to the IgG level.
Results: Baseline characteristics and interval period from VAD placement to transplant 
were similar in both groups. The incidence of bacteremia in the HGG group was signiﬁcantly 
increased compared to the control group (14/20 {70%} vs 18/56 {32%}, P=0.0032) and 
the incidence of any major infection (drive line, pump pocket, respiratory, mediastinal, 
intraabdominal) was also signiﬁcantly increased in the HGG group compared to control 
(19/20 {95%} vs 31/56 {56%}, P=0.0009). Following transpalntation, the episodes of 
rejection were similar in both groups and there was no signiﬁcant difference in survival. 
However, the HGG group experienced increased incidence of CMV infection compared to 
control (9/20 {45%}vs 9/56 {16%}, P=0.009).
Conclusions: This is the ﬁrst study to describe the impact of hypogammaglobulinemia 
in patients with ventricular assist devices. VAD patients with HGG are at increased risk 
of infections. Following transplantation, these patients also experience increased CMV 
infections. A randomized preemptive IgG replacement trial may be warranted in the future 
to alleviate the risk of infection.
1058-183 Awareness of Recommended Heart Failure Management 
Among Specialists. Do Internists, Geriatricians and 
Cardiologists Differ? - Results of SHAPE
Willem J. Remme, Faiez Zannad, Bernhard Rauch, John McMurray, Alain Cohen-Solal, 
Karen Keukelaar, Alessandro Boccanelli, Jose Lopez-Sendon, Richard Hobbs, Cezar 
Macarie, Rainer Dietz, Witold Ruzyllo, Charles Cline, Sticares Cardiovascular Research 
Foundation, Rhoon, The Netherlands
Background: Awareness of evidence-based heart failure (HF) management guidelines 
may differ between various health care providers. We studied how knowledge of the 
diagnostic and therapeutic strategies recommended in current HF guidelines varied 
amongst specialists involved in the care of patients with this condition, including internists, 
geriatricians and cardiologists.
Methods: The Study group on Heart failure Awareness and Perception in Europe 
(SHAPE) surveyed 4000 randomly selected medical specialists in France, Germany, Italy, 
the Netherlands, Poland, Romania, Spain, Sweden and the UK. Each specialist completed 
a 32 item questionnaire (in their native language) about their diagnosis and treatment of 
HF. Treatment questions related to heart failure with systolic dysfunction (LVEF<40%). In 
this analysis internists and geriatricians (I/G) were compared to cardiologists (C).
Results: 78% I/G and 90% C use echocardiography as a routine diagnostic test 
(p<0.0001), but 56% I/G and 58% C would use BNP/proBNP. Beta-blockade was 
considered the most important innovation in the last decade by 81% I/G and 95% C, 
angiotensin II antagonists by 54% I/G and 30% C, and cardiac resynchronization therapy 
and ICD by 17% I/G and 34% C (all p<0.0001). Only 39% I/G would use a beta-blocker 
in ≥ 50% of their patients, compared to 73% C (p<0.0001). ACE inhibitors would be 
prescribed in >90% of patients by 64% I/G and 82% C (p<0.0001). Recommended 
ACE inhibitor dose levels were prescribed by 26-76% I/G and by 40-89% C (p<0.0001). 
18% I/G would treat with diuretics only in mild, stable heart failure vs 7% C (p<0.0001). 
In patients with worsening heart failure, in sinus rhythm and on optimal doses of ACE 
inhibitors, beta-blockers and diuretics, 51% I/G and 59% C would add spironolactone 
(p<0.0001), whereas 14% I/G and 11% C would add digoxin.
Conclusion: Despite evidence-based guidelines, between-specialty differences in 
the management of heart failure persist. Signiﬁcantly less uptake of recommended 
management strategies in internist and geriatric practices indicates the need for education 
of these essential health care providers.
1058-210 Does Time From Symptom Onset to Hospital 
Presentation Inﬂuence Importance of Time From Door-
to-Balloon?
Robert L. McNamara, Yongfei Wang, Jeph Herrin, Jeptha Curtis, Elizabeth Bradley, 
David Magid, Eric Peterson, Martha Blaney, Paul Frederick, Harlan M. Krumholz, Yale 
University, New Haven, CT
Background: Some investigators have suggested that shorter door-to-balloon time 
leads to improved survival for patients with ST-segment elevation myocardial infarction 
(STEMI) treated with primary percutaneous coronary interventions (PCI) only for patients 
who present within 2 hours of symptom onset.
Methods: Cohort study of 29,668 STEMI patients treated with PCI at 421 hospitals who 
participated in the National Registry Myocardial Infarction from 1999-2002. We employed 
hierarchical models to evaluate the effect of door-to-balloon time on in-hospital mortality 
adjusted for patient characteristics among two groups of patients: those with symptom 
onset-to-door time ≤ 2 hours (N=18,313) versus those with symptom onset-to-door time 
> 2 hours (N=11,355).
Results: The relationship between door-to-balloon times and survival was similar for 
both groups of patients (Figure). Longer door-to-balloon times were associated with 
increased in-hospital mortality for patients with symptom onset-to-door time ≤ 2 hours 
and for those with symptom-onset-to-door time > 2 hours (p for trend <0.01 for both). In 
both groups, a 30 minute decrease in door-to-balloon time translated into a 6.1% (95% 
CI 3.0%-9.1%, p<0.001) improvement in relative mortality, corresponding to about a 0.3% 
improvement in absolute mortality.
Conclusion: Time to primary PCI is important regardless of symptom onset time. Efforts 
to shorten door-to-balloon time should apply to all patients.
1058-211 Q-Wave Myocardial Infarctions - Do We Treat Women 
Differently?
Aaron Kugelmass, Allan Anderson, Lynn Tarkington, Salvatore Battaglia, Steven Culler, 
Edmund Becker, April W. Simon, Emory University, Atlanta, GA, HCA, Inc., Nashville, TN
Background: While it is well known that women present with coronary heart disease at an 
older age than men, it is not clear in the Q-wave myocardial infarction (MI) population the extent 
to which there are gender-based differences in clinical outcomes and treatment patterns. We 
analyze Q-wave MI gender differences in a large community-based practice population.
Methods: Using the HCA Casemix Database, a comprehensive database of all consecutive 
patients in all HCA hospitals, 125,960 consecutive Q-wave MI admissions were analyzed 
for the 30-month period January 2002 through June 2004. Primary diagnosis of Q-wave MI, 
co-morbid conditions, procedures, and complications were identiﬁed through ICD-9 coding. 
Three Q-wave locations were differentiated: anterior, inferior, and posterior/lateral. Univariate 
and multivariate regression analyses controlling for 25 patient characteristics and comorbid 
conditions were used to analyze treatment patterns and patient outcomes: in-hospital mortality, 
neurologic complications, cardiac complications, and acute renal failure (ARF).
Results: The majority of Q-wave MI study patient admissions were men (67.9% vs. 32.1%). 
Univariate comparisons demonstrate that in-hospital mortality, neurologic complications, and 
ARF were higher for women than men despite the fact that men had more anterior MI. Men 
had higher rates of diagnostic catheterization, percutaneous coronary intervention (PCI), and 
coronary artery bypass graft surgery (CABG). Signiﬁcant risk-adjusted results indicated that 
men were 23.0% less likely to die and 30.4% more likely to be discharged home. Men were 
signiﬁcantly more likely than women to undergo diagnostic cath (14.3%), PCI (39.3%), and 
CABG (100.1%). This magnitude of difference was consistent for every MI location.
Conclusions: Even after risk-adjustment, women with Q-wave MIs have signiﬁcantly higher 
in-hospital mortality regardless of MI location. Men are signiﬁcantly more like to be treated 
invasively than women. Further research is necessary to determine the reasons for these 
gender differences and how women can achieve clinical outcome parity with men.
1058-212 Poor Graft Survival and Patient Survival After Primary 
PCI for AMI due to Saphenous Vein Graft Occlusion
Bruce R Brodie, Thomas D Stuckey, Charles Hansen, Scott J Richter, Debra S VerSteeg, 
Mark Brodie, Navin Gupta, Mark Pulsipher, William E Downey, LeBauer Cardiovascular 
Research Foundation, Greensboro, NC, Moses Cone Heart and Vascular Center, 
Greensboro, NC
Background: Primary PCI for AMI due to SVG occlusion has been associated with poor 
procedural results and poor short term outcomes, but long term graft patency and patient 
survival have not been evaluated.
Methods: Consecutive pts (n = 2,240) with STEMI treated with primary PCI from 1984-
2003 were followed for 6.3 yrs (median). Follow-up angiography following SVG PCI was 
obtained in 84% of hospital survivors at 7 mos (median).
Results: Pts with primary PCI for SVG occlusion (n = 57) vs native artery occlusion had 
more prior MI (49% vs 16%, p<0.0001), Killip class 3-4 (25% vs 16%, p=0.046), and 3 
vessel CAD (84% vs 22%, p<0.0001) and lower acute EF (46.1% vs 50.8%, p=0.03). 
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Pts with primary PCI for SVG occlusion had lower rates of TIMI 3 ﬂow post-PCI (80.7% 
vs 93.6%, p =0.0001), higher hospital mortality (21.1% vs 8.0%, p=0.0004) and lower 
follow-up EF (49.3% vs 54.7%, p=0.055). At one year 36% of culprit SVGs were occluded 
and 66% were occluded or required TVR. Survival free of infarct vessel re-occlusion 
was strikingly worse in pts with SVG vs native artery PCI (Figure). SVG PCI was the 2nd 
strongest predictor of late cardiac mortality (HR 2.11 95% CI 1.38-3.23, p=0.0006).
Conclusion: Pts with AMI due to SVG occlusion treated with primary PCI have poor acute 
procedural results, frequent late re-occlusion and TVR, and very high late mortality. The use of 
new technologies (DES and distal protection) may improve short term outcomes, but improved 
long term outcomes may require new and more aggressive revascularization strategies. 
1058-213 Dramatic Beneﬁt of Intensive Statin Therapy in Women: 
Results from PROVE IT-TIMI 22
Emily Rose, Carolyn McCabe, Richard Cairns, Christopher P. Cannon, Eugene 
Braunwald, Brigham and Women’s Hospital, Boston, MA
Dramatic Beneﬁt of Intensive Statin Therapy in Women: Results from PROVE IT-
TIMI 22
Background: Differences in coronary artery disease between women and men have 
been previously documented, which raises the potential that the efﬁcacy of various 
therapies may vary according to gender.
Methods: The characteristics and outcomes of 911 women and 3251 men enrolled in 
the PROVE IT-TIMI 22 were compared by intensive (atorvastatin 80 mg) vs. moderate 
(pravastatin 40 mg) lipid lowering with statins.
Results: Women were older, and more often had diabetes, hypertension, congestive 
heart failure, had higher TIMI risk scores, greater use ACE/ARB and Ca++ blockers at 
randomization and more often presented with unstable angina.(All p<0.05) Women had 
higher total cholesterol, HDL,(p<0.001) but similar LDL at baseline compared to men. 
Atorvastatin 80 mg decreased LDL by 37% in women and 43% in men (p<0.001). In 
women, intensive statin therapy decreased the rate of the primary endpoint (20.3% vs. 
27.0% for moderate statin therapy, a 25% risk reduction, p= 0.04). This absolute prevention 
of 7 events for every 100 women treated intensively compared with 3 events prevented for 
men (23.0% vs. 26.2%, a 14% risk reduction, p=0.039). Among women who underwent 
PCI for index ACS event, the protective effects of intensive statin therapy were even more 
striking, including decreased risk of the primary endpoint (19.5% vs. 28.5%, a 34% risk 
reduction, p=0.016), and of the composite of death, MI, or urgent revascularization 12.3% 
vs. 20.8%, a 42% risk reduction, p= 0.009. Intensive therapy also reduced the need for 
revascularization (>30 days post randomization, 15.7% vs. 21.6%, p=0.05) and need for 
urgent revascularization (10.5% vs. 16.6%, p=0.038). 
Conclusions: Women with ACS were older and had increased co-morbidity, and despite 
having slightly less LDL lowering than men, had a dramatic beneﬁt from intensive statin 
therapy. Women who had PCI for their ACS event had particular beneﬁt from intensive 
statin therapy including reductions in both clinical events and in the need for repeat 
revascularization. Thus, we have demonstrated that women post ACS beneﬁt from 
intensive statin therapy and they should be treated aggressively.
1058-214 Combined Community Based And On-site Responder A 
E D-system In Switzerland: 10 Fold Increased Longterm 
Survival Rate Of Out-of-hospital Cardiac Arrest
Cyrill J. Morger, Raymond Gaillet, Martin von Planta, Hugo Saner, University Hospital 
Bern, Bern, Switzerland
Background: To increase the survival rate after out-of-hospital cardiac arrest (OHCA) and 
to determine the beneﬁts of a combined mobile and on site AED-system (AED=automatic 
external deﬁbrillator).
Methods: From July 2000 >500 ﬁre ﬁghters and 20 railway station staff in the rural 
area of Olten (population 82’000) were trained in cardiopulmonary resuscitation (CPR) 
and semiautomatic deﬁbrillation during 4 hours. The 36 ﬁre ﬁghter teams used mobile 
AEDs and were alarmed by the emergency call center simultaneously with the EMS in 
every cardiac emergency. One AED was positioned at a strategic location with >20’000 
commuters/ day (railway station), where the staff intervened as on site responders. All 
participants were volunteers without previous medical training.
Results: During the study period of 2 years, 346 interventions were made by the teams 
(mean age 59±7.5 years). 51 needed CPR. 24% (n=12) of these were found in ventricular 
ﬁbrillation (VF), 69% (n=35) in asystole and 7% (n=4) had other rhythms. 19 were 
deﬁbrillated, 5 successfully (4 by ﬁre ﬁghters, 1 by railway station staff). These 5 aged 
42-79 years survived and left the hospital in good neurological conditions. Long term 
survival rate of OHCA increased from 1% before the study to 10%. The ﬁre ﬁghters (on 
site responders) reached the pts within a mean time of 4.5 min. (2.5 min.) after dispatch 
and arrived in 84% with a mean lead time of 6 min. before EMS.
Conclusions: Early deﬁbrillation by minimally trained lay persons signiﬁcantly increases 
the chances of survival of OHCA. A mixed system of mobile AEDs (ﬁre ﬁghters) and 
strategically positioned AEDs (i.e. railway station) seems to be the model of choice. Only 
24% were found in VF. This underlines the importance of population information in order 
to decrease reaction times in cardiac emergencies.
(Study supported by the Swiss Heart Foundation and the Olten Heart Foundation)
1058-244 Real-Time MRI Guided Aortic Coarctation Stent Repair 
is Safe and Feasible in a Swine Model
James D. Telep, Amish N. Raval, Michael A. Guttman, Cengizhan Ozturk, Michael Jones, 
Richard B. Thompson, Victor J. Wright, William H. Schenke, Ranil DeSilva, Ronnier J. Aviles, 
Venkatesh K. Raman, Michael C. Slack, Robert J. Lederman, Cardiovascular Branch/
National Heart Lung and Blood Institute/National Institutes of Health, Bethesda, MD
Background: Aortic coarctation stenting is currently performed using xray ﬂuoroscopy 
and exposes children to ionizing radiation. Real-time MRI guided stent delivery may be 
advantageous due to superior 3D tissue imaging, without radiation. We report safety and 
feasibility of real-time MRI guided stenting in a porcine surgical model of aortic coarctation 
entirely using commercially available catheter devices.
Methods: Coarctation stenting was performed in 9 swine using commercially available 
catheter devices in a combined X-ray/MRI (XMR) laboratory. MRI permitted successful 
and safe device navigation(A), positioning(B), deployment (C), balloon withdrawal(D) 
and hemodynamic measurements with assessment of stent apposition. “Active” antenna 
coil guidewires shortened procedure time compared with “passive” nitinol guidewires by 
improving device visualization. Baseline rest peak-to-peak catheter/after isoproteronol 
stress/peak instantaneous PCMRI gradient was 16.6 ± 7.7/33.8 ± 18.1/24.4 ± 6.7 
mmHg respectively. After stenting the rest peak-to-peak/peak instantaneous PCMRI 
gradient was reduced to 3.6 ± 2.7/7.8 ± 6.5 mmHg (both p<0.01 compared with baseline, 
respectively). Follow-up catheterization and necropsy showed durable gradient reduction 
and appropriate neointima formation.
Conclusion. Stent delivery for aortic coarctation entirely using rtMRI and commercially-
available catheter devices is safe and feasible. These data support initial clinical investigation. 
1058-264 The Distribution Of The Autonomic Nerves Around The 
Both Pulmonary Veins In Humans 
Taka-aki Matsuyama, Shin Inoue, Youichi Kobayashi, Kaoru Tanno, Testuo Sakai, 
Tsukasa Saito, Taku Asano, Takashi Katagiri, Hidekazu Ota, Third Department of 
Internal Medicine, Showa University School of Medicine, Tokyo, Japan
Background: Recent clinical studies suggest that the autonomic nerve imbalance is 
associated with the cause of atrial ﬁbrillation and the spontaneous initiation of atrial 
ﬁbrillation arise from the pulmonary veins (PVs). Although, the foci of the ectopic beats 
were frequently appeared around the both superior and left inferior PVs, the histological 
characteristics explaining this mechanism are practically unknown.
Methods: Sixteen autopsied hearts from individuals 43 to 94 years of age (mean 70.0 
years; 10 men and 6 women) were studied. Three hearts had atrial ﬁbrillation, others had no 
conspicuous atrial arrhythmia. Both atria were removed with all PVs stalks, both auricular 
appendages and superior and inferior vena cava and cut longitudinally to the each PV. 
After the staining with hematoxylin-eosin, azan-Mallory, and immunohistochemical s-100 
staining and tyrosine hydroxylase staining, the arrangements of the myocardial sleeve 
musculature and autonomic nerve distribution were focused under the microscope.
Results: Small nerve bundles were abundantly distributed beneath the epicardium of 
myocardial sleeve of the all PVs. In all hearts, abundant thick sympathetic nerve bundles 
that were positive with tyrosine hydroxylase were observed in the vicinity of the left veno-
auricular junction and the nerve bundles were also distributed among the myocardial 
cells. In 12 heats, bridged myocardial cells along the Marshall ligament were observed 
near the thick sympathetic nerve bundles. Although the thick sympathetic nerve bundles 
were not conspicuous around the right PV junction, many nodules of ganglion cells that 
were derived from parasympathetic nerves and ﬁne nerve bundles that were partially 
positive with tyrosine hydroxylase were also scattered in the epicardial fat of the right 
veno-atrial junction. Conclusions: The unique arrangement of sleeve musculature and 
autonomic nerve bundles at the both PVs oriﬁces seems to be relevant to the occurrence 
of spontaneous ectopic beats.
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1058-265 Natural History Of Asymptomatic WPW. Insights For 
Risk Stratiﬁcation And Management
Carlo Pappone, Giuseppe Augello, Francesco Manguso, Gabriele Paglino, Nicoleta 
Sora, Gabriele Vicedomini, Amedeo Ferro, Vincenzo Santinelli, San Raffaele University 
Hospital, Milan, Italy
Background - The natural history of the WPW remains unknown.
Methods - Data on natural history were collected from 477 untreated asymptomatic WPW 
subjects referred for electrophysiologic testing (EPT) and risk stratiﬁcation. Patients were 
grouped according to the age (> or < 25 yrs), inducibility on EPT, and the presence of 
multiple AP. 
Results - On the basis of life table survival analysis (Figure 1, p<0.001), patients were 
classiﬁed as being at Highest Risk (>50%), Intermediate Risk (20% to 50%) and Lowest 
Risk (<20%, Figure 2). Ventricular ﬁbrillation occurred in 7 Highest Risk subjects.
Conclusion - We have devised a novel model to stratify risk for future arrhythmic 
events, including ventricular ﬁbrillation among asymptomatic WPW subjects. Ablation is 
mandatory among Highest Risk subjects. 
1058-266 Atrial Arrhythmias are Frequently Undetected by 
Intermittent 24-Hour Monitoring
Paul Ziegler, Jodi Koehler, Medtronic, Inc., Minneapolis, MN
Background: Patients with atrial tachyarrhythmias and atrial ﬁbrillation (AT/AF) are 
at an increased risk of stroke and mortality. However, AT/AF episodes are frequently 
asymptomatic and unlikely to be reported. We assessed whether 24-hour monitoring on 
annual or quarterly intervals adequately identiﬁed patients with AT/AF episodes compared 
to implantable devices.
Methods: Data from 574 pacemaker (AT500, Medtronic) patients (70±12 years) with a 
brady pacing indication, ≥ 1 symptomatic AT/AF episode in the 3 months prior to implant, 
and ≥ 365 days of follow-up were analyzed. The device records daily AT/AF burden over 
the past 14 months with > 95% sensitivity. Intermittent 24-hour monitoring was simulated 
by selecting the AT/AF burden on pre-speciﬁed day(s) from device memory. Annual 
monitoring occurred on day 365 of the follow-up while quarterly monitoring occurred on 
days 90, 180, 270, and 360. The average burden over the ﬁrst 365 days after implant was 
also calculated for each patient.
Results: A total of 434 patients (76%) did not have any AT/AF burden recorded on the day 
of the annual 24-hour measurement. In these patients, the median burden over the entire 
year was 0.11 (0.0001-1.05) hours/day, which was signiﬁcantly greater than indicated by 
intermittent monitoring (p<0.001, Sign test). Quarterly 24-hour monitoring resulted in 312 
patients (54%) with no AT/AF burden on any of the 4 selected days of monitoring. The 
median burden for these patients over the entire year was 0.02 (0.00-0.27) hours/day, 
which was also greater (p<0.001) than indicated by intermittent monitoring. Furthermore, 
25.4% and 8.3% of pts averaged >1 hour/day of AT/AF burden over the entire year despite 
having no AT/AF detected during annual or quarterly monitoring, respectively.
Conclusions: In patients with a history of AT/AF, annual or quarterly 24-hour monitoring 
frequently fails to detect patients with signiﬁcant AT/AF burden. Chronic monitoring by 
implantable devices or recorders may reduce stroke risk by identifying AT/AF that would 
otherwise go undetected.
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1116-1 Delayed Healing and Persistent Inﬂammation at Sites 
of Overlapping Sirolimus and Paclitaxel Drug-Eluting 
Stents
Aloke V. Finn, Frank D. Kolodgie, Eduardo Acampado, L.J. Guerrero, Kirubel Tefera, 
Deena K. Weber, Herman K. Gold, Renu Virmani, Armed Forces Institute of Pathology, 
Washington, DC, Massachusetts General Hospital, Boston, MA
Background: Effective coverage of challenging coronary lesions has lead to the frequent 
use of overlapping drug-eluting stents. The histopathologic response to stent overlap is 
unknown.
Methods: The arterial response to overlapping sirolimus- (SES) and paclitaxel-eluting 
stents (PES) was examined. Single iliac artery balloon injury was followed by placement 
of two overlapping 3.0 mm diameter SES or PES in 26 anesthetized rabbits (mean length 
of overlap= 9.6 mm). The stented arterial segments were harvested at 28 and 90 days and 
processed for light microscopy.
Results: At 28 days, vascular healing was delayed at overlap compared to non-
overlapped sites. At overlap, PES signiﬁcantly induced more luminal eosinophils and peri-
strut ﬁbrin than SES; peri-strut giant cell inﬁltration however, was more frequent in SES. 
Although neointimal growth in both stents was greater at 90 days, sustained suppression 
of neointima was not maintained in the overlapped segments of PES. No differences in 
cell proliferation were observed. Notably, medial cell density underneath stent struts was 
signiﬁcantly lower with PES vs. SES at both 28 and 90-days (p< 0.04). 
Groups Neointimal thickness (mm)
No. struts surrounded 
by Fibrin No. of eosinophils 
Overlap 28 days 90 days 28 days 90 days 28 days 90 days
SES 0.09±0.04
0.08±
0.01 10±5 3±3# 33.8±29.5 9.5±18
PES 0.07±0.03
0.13±
0.01* 15±5 6.±7 ^ 89.5±64.1 52.3±18.8 #
P value ns 0.008 0.03 ns 0.03 0.03
28 days vs. 90 days, *p = 0.02; #p=0.01; ^p=0.03
Conclusions: Both stent types provoke delayed healing and inﬂammation at overlapping 
sites. PES induced greater ﬁbrin deposition, medial necrosis, eosinophilic inﬁltrate and 
late neointimal proliferation than SES. Close follow-up care is prudent for those patients 
receiving overlapping drug-eluting stents.
1116-5 Thermal Heterogeneity In Culprit And Non-culprit 
Lesions In Patients With Acute Coronary Syndromes: 
Local Or Widespread?
Konstantinos Toutouzas, Maria Drakopoulou, Sophia Vaina, John Mitropoulos, 
Eleftherios Tsiamis, Manolis Vavuranakis, Aris Androulakis, Virginia Markou, 
Christodoulos Stefanadis, Hippokration Hospital, Athens, Greece
There is a controversy whether vulnerable plaques are multiple due to diffuse inﬂammation, 
or limited to the culprit lesion. By coronary thermography the local inﬂammatory 
involvement can be assessed and it has been shown marked thermal heterogeneity in 
culprit lesions, especially in patients (pts) with acute coronary syndromes (ACS). We 
investigated whether there is widespread thermal heterogeneity both in culprit and non-
culprit lesions in pts with ACS.
Method: We included pts with ACS undergoing percutaneous coronary intervention. All pts 
had at least 2 angiographically signiﬁcant lesions (stenosis>50%) at different arteries. Culprit 
lesions were identiﬁed in all patients by a combination of ECG, wall motion abnormalities, 
scintigraphic perfusion defects, and coronary angiogram. We measured at each lesion the 
temperature difference (DT) between the atherosclerotic plaque and the proximal vessel 
wall temperature using a thermography catheter (Medispes, ZWG, Switzerland) .
Results: Coronary thermography was performed in 34 lesions (n=17 pts). The majority of 
pts was receiving statins (73%). The procedure was safe, without complications. Thermal 
heterogeneity (≥0.050C) was detected in 11 (65%) in culprit and in 12 (70%) (p=0.99) in 
non-culprit lesions. In culprit lesions without thermal heterogeneity, in non-culprit lesions 
there was no increase in temperature in non-culprit lesions. Mean DT was similar in culprit 
lesions and non-culprit lesions (0.13±0.14 vs 0.14±0.140C, p=0.99). 
Conclusion: Although a single lesion is clinically symptomatic, acute coronary syndromes 
seem to be associated with diffuse thermal heterogeneity. The results of this study 
demonstrate the diffuse inﬂammatory activation in acute coronary syndromes.
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1116-6 Left Atrial Appendage Occlusion to Prevent Stroke in 
Sub-Optimal Warfarin Candidates: Current Results of 
the European Multicenter Registry Trial
Evelyn Fischer, Heyder Omran, Leif Thuesen, Maximilian Pichler, Edward Rowland, 
Antonio Bartorelli, Pedro Brugada, P. W. Serruys, Werner Budts, Angelo Ramondo, 
Alec Vahanian, Peter Probst, Gilles Montalescot, Jean-François Piéchaud, Karl-Heinz 
Kuck, Witold Ruzyllo, Jean Marco, Thomas Wichter, Eulogio Garcia, Eustaquio Onorato, 
Yves Bayard, Stefan Ostermayer, Franziska Büscheck, Michaela Leetz, Horst Sievert, 
CardioVascular Center Frankfurt, Frankfurt am Main, Germany
Background: Open heart surgery being invasive and risky, transcatheter occlusion of 
the left atrial appendage offers a sparing alternative in patients who are suboptimal 
warfarin candidates. The PLAATO™ (Percutaneous Left Atrial Appendage Transcatheter 
Occlusion) Feasibility Study ﬁnished in January 2003 proved the safety and feasibility 
of this procedure. The larger European PLAATO™ registry trial with a main focus on a 
possible risk reduction is still ongoing.
Methods: The study is designed for 156 patients. Inclusion criteria were atrial ﬁbrillation 
(AF) with inability to take warfarin, prior cerebral ischemia and/ or two clinical risk factors 
for stroke. After implantation of the occluder, the patients were followed with X-ray, TEE 
and NIH stroke scale in regular intervals.
Results: 92 patients (67% male) with a mean age of 70 ± 9 years were enrolled so far. All 
candidates were successfully implanted. The mean procedure time was 76± 36 minutes and 
the mean left atrial appendage oriﬁce diameter was 20 ± 3 mm. During a total follow up time 
of 51 years, one patient died of a brochial carcinoma diagnosed 3 months before the one year 
follow up. According to the CHADS2 score, the mean expected annual risk of stroke for the 
patients enrolled is 4,2%. One patient sustained a stroke six months post implant. Thus, the 
yearly incidence of stroke after implantation is 1,9%. The estimated risk reduction is 55%.
In three patients, a thrombus on the occluder was found prior to hospital discharge (2) 
and one month after the procedure (1). All thrombi were resolved without sequelae. One 
device was chosen too small and embolized into the aorta after its release. It could be 
snared with a catheter and was retrieved successfully. Another device was implanted in 
the very same procedure.
Conclusion: Our experience with the PLAATO™ registry study shows that the incidence 
of stroke in high-risk patients decreases after implantation of the device. Therefore, this 
method should be considered in all patients unable or unwilling to take warfarin.
1116-7 Intracoronary Enalaprilat Induces Cardiac 
Preconditioning during Percutaneous Transluminal 
Coronary Angioplasty
Hani Jneid, Massoud A. Leesar, University of Louisville, Louisville, KY
Background: Preconditioning (PC) is the phenomenon whereby a sub-lethal insult to the 
heart renders it resistant to subsequent ischemia. Previous animal studies demonstrated 
the PC-mimetic actions of angiotensin converting enzyme inhibitors (ACE-Is). We 
hypothesized that enalaprilat exert PC-mimetic effects in patients with coronary artery 
disease undergoing angioplasty procedures.
Methods: Prior to the start of planned angioplasty, 22 patients were randomized to 
receive 15-min intracoronary infusions of enalaprilat (0.05 mg/min) or placebo (saline), 
followed by an ischemic PC protocol (consisting of 3 balloon inﬂations, each lasting 120 
s, interspersed with 5-min reperfusion). The sums of ST-segment shift, measured on 
intracoronary and surface electrocardiograms (ECGs), and chest pain score, assessed 
using a visual-analog scale, during balloon inﬂation were used as the study end-points.
Results: The sum of ST-segment shift in the placebo group was greater during the ﬁrst 
balloon inﬂation than during the second and third inﬂations on both the intracoronary (21.0 
± 2.8 vs.13.0 ± 2.0 and 13.0 ± 2.0 mm, P <0.05) and surface ECGs (16.0 ± 4.0 vs. 10.0 
± 2.0 and 9.0 ± 2.0 mm, P < 0.05). The enalaprilat group, however, showed no changes 
in ST-segment shift among inﬂations on either the intracoronary (10.0 ± 2.0 vs. 10 ± 2.0 
and 9.0 ± 2.0 mm, P= NS) or surface ECGs (8.0 ± 2.0 vs. 8.0 ± 2.0 and 8.0 ± 2.0 mm, P= 
NS), indicating that enalaprilat preconditioned the heart maximally starting with the ﬁrst 
inﬂation. Similarly, the chest pain score showed signiﬁcant decrease with serial inﬂations 
in the placebo group (64.0 ± 6.0 vs. 49.0 ± 8.0 and 40.0 ± 8.0 mm, P< 0.05), but not in the 
enalaprilat group (P= NS). The cardioprotective effects of enalaprilat were independent 
of changes in rate-pressure product, coronary blood ﬂow or minimal coronary luminal 
diameter, as no signiﬁcant changes in these measurements at baseline and shortly after 
the end of infusion were detected.
Conclusion: This is the ﬁrst evidence in humans that an ACE-I preconditions the heart 
against ischemia. The PC-mimetic effect of ACE-Is is a novel action through which these 
drugs exert salutary cardiac effects and needs further exploration.
1116-54 Surgical Correction Of Mitral Regurgitation In The 
Elderly: Risks And Recent Improvements
Delphine Detaint, Thoralf Sundt, Vuysile Nkomo, Hartzell Schaff, Christopher Scott, 
Jamil Tajik, Maurice Enriquez-Sarano, mayo clinic, rochester, MN
Background: In the elderly, prevalence of mitral regurgitation (MR) is high but risk of surgery 
is also high. Therefore beneﬁts and indications of MR surgery are uncertain in the elderly.
Methods: The outcome of 1344 patients (pts) operated in 1980-1995 for severe MR was 
analyzed by age <65, 65-74 and ≥75 (n=556, 504, 284).
Results: At baseline, prevalence of severe symptoms, atrial ﬁbrillation, coronary 
disease, ischemic MR, need for bypass surgery and creatinine level were higher in older 
vs. younger pts (all p<0.002). Operative outcome: Operative risk was higher in elderly 
but there was a marked decrease in operative mortality (ﬁgure left) and in low output state 
(ﬁgure center), and a considerable increase in valve repair (ﬁgure right) over time (all 
p<0.0001), particularly in the elderly. Long-term survival: Elderly vs. younger pts had 
lower late survival (at 5 year, <65: 88±1, 65-74:79±2, ≥75:64±3%, p<0.001). However, 
relative survival (ratio of observed/expected survival) was similarly good in all age groups 
(at 5-year, 92.7% for <65, 92.9% for 65-74, 92.7% for ≥75 years).
Conclusion: Elderly pts undergoing MR surgery display more severe preoperative clinical 
characteristics, and incur higher operative risks vs. younger pts. However outstanding 
recent surgical improvements resulted in considerably improved outcomes in the elderly 
suggesting that surgery should not be denied on the basis of age alone and should be 
performed before overt heart failure.
 
1116-58 Evaluation of a Safety Protocol for Clinically Indicated 
Magnetic Resonance Imaging of Patients with 
Permanent Pacemakers and Implantable Deﬁbrillators 
at 1.5 Tesla
Saman Nazarian, Ariel Roguin, Menekhem M. Zviman, Albert C. Lardo, Timm L. 
Dickfeld, Ronald D. Berger, David A. Bluemke, Henry R. Halperin, Johns Hopkins 
Hospital, Baltimore, MD
Background: A recent case series reported the overall safety of magnetic resonance 
imaging (MRI) for patients with pacemakers, without device selection and programming, 
or limits on speciﬁc absorption rate (SAR) of imaging sequences. However, increased 
thresholds and activation and inhibition of pacing were noted acutely, and chronic effects 
were not evaluated. We tested the acute and chronic safety of a protocol that limits SAR, 
and utilizes device selection and programming to reduce adverse effects.
Methods: Patients with clinical indication for MRI, and devices (15 pacemakers, 9 
implantable deﬁbrillators) shown to be safe by in vivo animal testing (SAR up to 3.5 W/
kg), were enrolled. Pacing mode was changed to asynchronous for pacemaker dependent 
patients, and ventricular inhibited for others. Magnet response and tachyarrhythmia 
functions were disabled. Blood pressure, ECG, and symptoms were monitored. SAR was 
limited to 2.0 W/kg for all sequences. Device parameters were assessed immediately post 
MRI and at chronic follow-up (median 24 days after MRI).
Acute Mean 
Difference P
Chronic Mean 
Difference P
Atrial Capture (V) 0.0±0.2 0.718 0.3±0.4 0.500
Ventricular Capture (V) 0.0±0.1 0.912 0.0±0.3 0.704
Battery Voltage (V) 0.0±0.0 0.430 0.0±0.0 0.391
Results: No episodes of inappropriate inhibition or activation of pacing were observed 
during MRI. There were no signiﬁcant differences between acute or chronic and baseline 
device parameters (Table). Minimal susceptibility artifacts were noted on inversion 
prepared gradient echo and steady state cine sequences.
Conclusion: Diagnostic MRI can be safely performed in patients with selected 
pacemakers and implantable deﬁbrillators.
1116-61 The Prognostic Value of Stress SPECT Tc 99m 
Tetrofosmin Imaging in Patients with the Metabolic 
Syndrome: Results from the Multicenter Myoview 
Registry
Leslee J. Shaw, Robert Hendel, Naomi Alazraki, Salvador Borges-Neto, Manuel 
Cerquiera, Jamshid Maddahi, Cedars-Sinai Medical Center, Los Angeles, CA, UCLA 
Medical Center, Los Angeles, CA
Background: The MetSyn represents a constellation of risk factors resulting from insulin 
resistance, dyslipidemia, hypertension, and obesity placing an individual’s coronary 
disease risk as intermediate between normal glucose homeostasis and diabetes. From a 
multicenter prospective registry of 7,849 patients, we evaluated the relationship between 
the MetSyn and risk stratiﬁcation with stress Tc-99m Tetrofosmin SPECT.
Methods: Scans were interpreted with a 20 segment myocardial model. A summed 
stress score was calculated from normal (0-3), mildly (4-8), moderately (9-13), to severely 
abnormal (>13). A Cox proportional hazards model was used to estimate cardiac death or 
myocardial infarction (D or MI, n=752).
Results: Of 7,849 patients (mean age=62 years, 37% women), 27% had the MetSyn. 
MetSyn patients had an 84% 2-year event-free survival; lower than patients with normal 
metabolic status (p<0.0001). In patients with the MetSyn, the % of moderate-severely 
abnormal SPECT ranged from 11% to 44% for those with 3 to 5 risk factors for the 
MetSyn. The ﬁgure plots relative risks of D or MI by the number of MetSyn risk factors 
revealing an additive relationship with SPECT abnormalities (p<0.0001). Patients with all 
5 risk factors for the MetSyn were at highest risk with relative risk ratios from 7.8- to 14.1-
fold for a mild to severely abnormal SPECT.
Conclusions: For patients with the metabolic syndrome, the presence of stress perfusion 
abnormalities is a harbinger for near-term major cardiovascular events.
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1116-62 Focal Stress Induced LV Geometry Changes 
Independently Predict Presence of the Angiographically 
Signiﬁcant CAD in Patients Undergoing Myocardial 
Perfusion SPECT
Aiden Abidov, Piotr J. Slomka, Hidetaka Nishina, Sean W. Hayes, John D. Friedman, 
Xingping Kang, Louise E. J. Thomson, James Gerlach, Guido Germano, Daniel S. 
Berman, Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: In this study we sought to determine the diagnostic value of stress-induced 
focal left ventricular (LV) geometry changes, expressed as a stress-rest difference in 
the maximal short-axis (SA) systolic radial dimension (SRD) in pts undergoing gated 
myocardial perfusion SPECT (MPS) for detection of angiographically signiﬁcant CAD, 
and to compare it to that of conventional TID ratio.
Methods: The study population was comprised of 240 pts (58% males, age 66± 12 yr) with 
no history of CAD who underwent coronary angiography <3 months after MPS. SRD was 
measured using a novel automatic algorithm: for each SA plane, the maximal dimension 
of the LV was found from the raw 3D contours derived by the QGS software, searching 
for the maximum distance between two endocardial points. TID ratio was measured 
automatically by QPS. Perfusion was visually assessed with calculation of summed stress 
perfusion scores (SSS), using 20-segment/5-point score. Logistic regression analysis was 
applied to assess unadjusted and adjusted (* for SSS and stress LVEF) prediction of 
angiographically signiﬁcant CAD (any CAD≥ 70% stenosis, CAD70) as well as any CAD≥ 
90% (CAD90), and severe and extensive CAD (≥ 90% proximal CAD, and/or multivessel 
CAD≥ 90%; S+E CAD)
Results: see Table.
CAD70 (n=165) CAD90 (n=131) S+E CAD (n=81)
SRD:
Unadjusted OR (95% CI) 
(per each 0.1 cm)
1.222 (1.114-1.341); 
p<0.001
1.171 (1.078-1.273); 
p<0.001
1.191 (1.089-1.302); 
p<0.001
Adjusted *OR (95% CI) 
(per each 0.1 cm)
1.165 (1.043-1.300); 
p=0.007
1.105 (1.007-1.211); 
p=0.034
1.131 (1.024-1.248); 
p=0.015
TID ratio:
Unadjusted OR (95% CI)
21.695 (3.399-138.458); 
p=0.004
10.951 (2.178-55.051); 
p=0.001
65.521 (11.136-386.092); 
p=0.004
Adjusted *OR (95% CI) 5.734 (0.592-55.503); p=0.132
2.820 (0.460-17.284); 
p=0.262
18.622 (2.797-123.982); 
p=0.003
Conclusion: SRD is a novel scintigraphic marker, superior to TID ratio and providing 
incremental information over SSS and LVEF in predicting the presence of CAD70, CAD90 
and S+E CAD.
1116-113 Picotamide, an Inhibitor of Thromboxane A2 Synthase 
and Receptor, Decreases Mortality in Diabetics With 
Peripheral Arterial Disease: The DAVID Study.
Gian Gastone Neri Serneri, Sergio Coccheri, Ettore Marubini, Francesco Violi, University 
of Florence Medical School, Florence, Italy, University of Bologna Medical School, 
Bologna, Italy
Background: Patients with diabetes are at excessive risk of mortality and cardiovascular 
morbidity and previous studies suggest that aspirin may be scarcely effective in diabetic 
subjects. In this multicenter double blind trial picotamide, a dual inhibitor of thromboxane 
A2 synthase and receptor, was compared with aspirin in prevention of mortality and major 
cardiovascular events in diabetics with Peripheral Arterial Disease (PAD).
Methods: A series of 1, 209 adults of both sexes, with type 2 diabetes and associated 
PAD were randomised to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 
months. Primary endpoint was death for any cause, and comparison between the two 
arms was made by log-rank test. Secondary endpoint was combined total mortality and 
non fatal cardiovascular events, compared between the two arms by using Gray’s test.
Results: Mortality signiﬁcantly dropped amongst patients who received picotamide (3.0%) 
rather than aspirin (5.5%: relative risk ratio 0.55; CI: 0.31-0.98). The secondary endpoint 
including mortality and cardiovascular morbidity was also lowered with picotamide versus 
aspirin, although not signiﬁcantly.Conclusion: Picotamide, a combined inhibitor of 
Tromboxane A2 synthase and receptor, was able to cut down overall mortality in type 2 
diabetics with PAD, proving almost twice as effective as aspirin in this setting.
1116-114 Diagnostic Role of New Doppler Index in Assessment of 
Renal Artery Stenosis
Sergio Chain, Hector Luciardi, Soﬁa Berman, Gabriela Feldman, Nicasio Herrera, Javier 
Ochoa, Juan Muntaner, Ricardo Ronderos, Eduardo Escudero, Centro Modelo de 
Cardiologia, Tucuman, Argentina
Background: Renal artery stenosis (RAS) is one of the main causes of secundary 
systemic arterial hypertension. Several non invasive diagnostic methods of RAS have 
been used in hypertensive pts such as Color Doppler Ultrasound. The aim of this study 
was to assess sensitivity and speciﬁcity of the conventional renal color Doppler direct 
parameters for the diagnosis of severe stenotic renal artery: renal peak systolic velocity 
(RPSV), and renal aortic ratio (RAR). A new velocity index was also proposed: the 
renal-renal index (RRI) and it was compared with conventional parameters in terms of 
sensitivity and speciﬁcity.
Methods: Our study group included 34 pts with severe arterial hypertension (21 males, 
mean age 54 ± 27 years) consecutively observed. Renal angiography was performed in 
all of our pts, RAS was considered signiﬁcant if a diameter reduction > 70% was found. 
The direct parameters measured were: 1) RPSV as the highest systolic Doppler velocity at 
the main renal artery. 2) RAR as the rate between RPSV and aortic peak systolic velocity 
measured at the abdominal aorta. 3) RRI as the rate between RPSV and renal peak 
systolic velocity measured at the renal hilum in its extraparenchymal segment. Doppler 
severe stenosis was considered signiﬁcant when RPSV > 200 cm/s and RAR > 3. The 
optimal sensitivity and speciﬁcity cutoff with ROC curve of the new RRI was >2,7.
Results: The accuracy of direct parameters for severe RAS were: 1) RPSV > 200 cm/
s: 97% sensitivity, 72 % speciﬁcity, 81% positive predictive value and 95% negative 
predictive value. 2) RAR > 3: 77% sensitivity, 90% speciﬁcity, 90% positive predictive 
value and 76% negative predictive value. 3) New RRI > 2,7: 97% sensitivity (p<0,07), 96% 
speciﬁcity (p<0,02), 97% positive predictive value, 97% negative predictive value.
Conclusions: The new RRI was used with improved speciﬁcity and high sensitivity 
compared to conventional direct parameters: RPSV > 200 cm/s and RAR > 3.
1116-115 Prognostic Implications Of Left Ventricular Mass 
Among Hispanics: The Northen Manhattan Study 
Carlos J. Rodriguez, Fay Lin, Ralph L. Sacco, Robert R. Sciacca, Bernadette Boden-
Albala, Rui Lui, Shunichi Homma, Marco R. Di Tulio, Columbia University, New York, NY
Background: Left ventricular mass (LVM) is reported to be more prevalent and LVM 
outcomes worse among blacks than whites. Hispanics may carry a similar burden of LVM as 
blacks but whether LVM portends a worse outcome among Hispanics is largely unknown. 
Methods: A population-based sample was identiﬁed to examine the relationship between 
LVM and cardiovascular mortality rates among Hispanics. We prospectively evaluated 
1081 Hispanics enrolled in the Northern Manhattan Study over the period of 1993 to 
2001. Subjects were 40 years or older and free of prior myocardial infarction or stroke. 
LVM was deﬁned echocardiographically and indexed for height2.7. Cox proportional 
hazards models were used to assess risk of cardiovascular events with adjustments for 
age, gender, systolic blood pressure, diabetes, hypercholesterolemia, smoking, and BMI. 
Results: Among Hispanics LVM averaged 48.4+/-1.5 gm/ht2.7 and was signiﬁcantly 
associated with the combined end-point of myocardial infarction, vascular death, or stroke 
[HR 1.41 per SD change in LVM (95% conﬁdence interval 1.16-1.70)]. During a mean 
of 52 months of follow up, 64 cardiovascular events occurred (myocardial infarctions, 
strokes, or vascular deaths). The annual rate of cardiovascular events was 2.23% in the 
highest quartile of LVM and 0.08% in the lowest quartile (P=0.0045). 
Conclusions: These data demonstrate in a large population-based sample that 
increasing LVM yields independent prognostic signiﬁcance among Hispanics, predicting a 
higher incidence of cardiovascular disease events in this understudied population.
1116-117 AT1-Receptor Autoantibodies in a Transgenic Animal 
Model for Preeclampsia
Ralf Dechend, Gratze Petra, Erdenschimig Shagdarsuren, Catherine Luyten, Gerd 
Wallukat, Jan-Hinrich Braesen, Dominik Mueller, Robert Pijnenborg, Rainer Dietz, 
Friedrich C. Luft, Franz-Volhard Clinic, Berlin, Germany, Experimenteel Laboratorium 
Gynecologie Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
We previously described activating autoantibodies against the Angiotensin 1 Receptor 
(AT1-AA) in patients with preeclampisa that are not present in patients with normal 
pregnancy. We showed earlier that female rats transgenic for human angiotensinogen 
mated with rats transgenic for human renin develop gestational hypertension. We relied 
on this model to search for AT1-AA with a beating neonatal rat cardiomyocyte bioassay. 
Telemetry BP increased in the third trimester of pregnancy (day 14) from 105/80 mmHg 
to as high as 170/140 mmHg and returned to normal after delivery. Echocardiographic 
dp/dt was also increased. The opposite cross and Sprage Dawley dams mated with sires 
transgenic for human renin had normal blood pressures throughout pregnancy. Proteinuria 
was increased from 0.1 mg/dl in the two control groups to 8.2 mg/dl in the hypertensive 
group. Further, macrophage and T lymphocytes were signiﬁcantly increased, compared 
to controls. Renal immunohistochemistry showed glomerular pathology with increased 
ﬁbrin expression, C1q and C3 complement fractions, and IgG. Vessels were detected 
in the myometrial triangle of the placenta that featured atherosis. Trophoblast invasion 
not normal. AT1-AA were not detected before the pregnancy. However, by day 18 of 
pregnancy, the AT1-AA assay was positive. We present a rat model of preeclampsia 
that features hypertension, proteinuria, and AT1-AA. This model should greatly facilitate 
investigations regarding the pathogenic signiﬁcance of AT1-AA.
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1116-151 B-type Natriuretic Peptide Infusion Improves Systolic 
Dysfunction and Attenuates Ventricular Remodeling in 
an Experimental Model of Myocardial Infarction
Steve Xydas, Stefan Klotz, Ilan Hay, Chuck Ng, Jonathan S. Chang, Timothy Martens, 
Zhihe Li, Andrew Protter, Mehmet C. Oz, Jie Wang, Columbia University College of 
Physicians and Surgeons, New York, NY, Scios Inc., Fremont, CA
Background: The beneﬁt of exogenous BNP in heart failure (HF) exacerbations has 
been shown, but its role after myocardial infarction (MI) is unknown. We hypothesized 
that BNP delivered post-MI would improve cardiac function and prevent left ventricular 
(LV) remodeling.
Methods: MI was induced by LAD ligation in rats and conﬁrmed by echocardiography. 
50 rats were randomized to 1 of 3 groups: MI + saline; MI + low-dose BNP (200 ng/kg/
min); or MI + high-dose BNP (400 ng/kg/min). Sham surgery was performed in another 
group without MI. Infusions were delivered for 7 days via venous catheters tunneled to an 
infusion pump. Rats were followed for 7 wks. Echocardiography, hemodynamics and in 
vivo and ex vivo pressure-volume relationships (PVR) were then obtained.
Results: Rats with MI developed HF vs. Sham rats, with a reduced fractional shortening 
(FS) and increased LV end-diastolic pressure. High-dose BNP attenuated the decline in 
FS vs. low-dose BNP. LV systolic pressure, dP/dtmax, dP/dtmin, heart weight and myocyte 
size improved with high-dose BNP treatment over control MI. Ex vivo end-diastolic PVR 
curves revealed no difference between high-dose BNP and Sham groups. Serum BNP 
levels increased during therapy, conﬁrming delivery of BNP vs. other groups.
Conclusion: We demonstrate improved LV contractile function and decreased LV 
remodeling with BNP infusion in an experimental MI model. These ﬁndings implicate a 
paracrine mechanism of action and may provide insight into a novel therapy to prevent 
HF after MI. 
Control MI Low-dose BNP Infusion
High-dose BNP 
Infusion Sham Surgery
Endpoint FS (%) 19 ± 4.4 *** 16 ± 5.7 *** 25 ± 13 ** 47 ± 6.6
% Change in FS (week 1 to 8) -33 ± 11 *** -36 ± 32 *** -16 ± 40 *** † -10 ± 10
LV EDP (mmHg) 10 ± 2.7 * 9.5 ± 5.8 * 5.7 ± 2.1 3.4 ± 1.5
LV SP (mmHg) 110 ± 4.3 ** 120 ± 10 132 ± 12 ‡ 132 ± 7.3
Max dP/dt (mmHg/sec) 5816 ± 846 *** 6599 ± 928 ** 8097 ± 841 ‡ § 8636 ± 853
Min dP/dt (mmHg/sec) -4707 ± 1054 *** -4905 ± 1250 *** -6793 ± 578 ‡ § -7608 ± 340
Cardiac Output (mL/min) 64 ± 13 59 ± 17 * 96 ± 30 † 94 ± 18
Heart Weight (gm) 1.8 ± 0.21 ** 1.8 ± 0.24 ** 1.7 ± 0.16 * ‡ § 1.4 ± 0.09
Myocyte Size (mcm) 23 ± 1.9 21± 2.8 19 ± 1.7 ‡ 20 ± 0.90
Notes: * p<0.05 vs. Sham, ** p<0.01 vs. Sham. *** p<0.001 vs. Sham. ‡ p<0.01 vs. control HF group. § 
p<0.05 vs. low-dose BNP. † p<0.01 vs. low-dose BNP.
HF = heart failure, BNP = b-type natriuretic peptide, FS = fractional shortening, LV = left ventricular, EDP = 
end-diastolic pressure, SP = systolic pressure, Max = maximum, Min = minimum.
1116-152 Transient Reestablishment Of Stem Cell Homing Via 
Cellular Cardiomyoplasty Improves Cardiac Function In 
Ischemic Cardiomyopathy
Indu Deglurkar, Zoran Popovic, Samuel Unzek, Matthew Kiedrowski, Kai Wang, Patrick 
McCarthy, Marc S. Penn, Cleveland Clinic Foundation, Cleveland, OH
Objective: The chronic expression of the stem cell homing factor SDF-1 results in 
improved cardiac function in animals with ischemic cardiomyopathy. However, the chronic 
expression of SDF-1 could lead to untoward effects including hemangioma formation. The 
goal of this study was to determine if establishing transient expression of SDF-1 through 
the transplantation of adenovirally infected skeletal myoblasts (SKMB) is sufﬁcient to 
recover cardiac function.
Methods: A third generation adenovirus encoding the human SDF-1 gene driven by a 
CMV promoter was generated. SKMB were infected 18 h before SKMB transplantation 
with AdSDF-1-myc (Study Group 1) or AdGFP (Study Group 2). Anterior myocardial 
infarction was induced in 31 male Lewis rats by direct ligation of the proximal left anterior 
descending artery. After 6 weeks, redo-sternotomy was performed on 23 rats. Study group 
I (n=15) received in the peri-infarct zone one million autologous SKMB transfected with 
hSDF-1 in 5 divided doses. Study Group II (controls n=8) received one million SKMB 
transfected with GFP. Echocardiograms were performed post-infarction and 4 weeks after 
cell transplantation.
Results: Shortening fraction in Study Group I, from 9.8%±2.8% to 14.7%±3.3% (P=.005), 
but changed from only 8.0%±5.2% to 9.5%±3.1% (P=0.005) in Control Group II at 4 
weeks. Immunohistochemistry in the infarct zone revealed signiﬁcantly greater vascular 
density in those animals that received SDF-1 expressing SKMB. Localization of SDF-1 
through immunostaining for myc suggests that SDF-1 is taken up by cardiac myocytes in 
the infarct border zone.
Conclusion: The transient expression of the stem cell homing SDF-1 through the 
transplantation of genetically modiﬁed autologous SKMB at a time remote from myocardial 
infarction is sufﬁcient to improve cardiac function, partly through the recruitment of new 
blood vessels, and partly through anti-apoptotic effects of SDF-1 uptake by cardiac 
myocytes in the infarct border zone. These data suggest a novel therapeutic strategy to 
improve left ventricular function without the need to introduce cells that are genetically 
altered permanently.
1116-153 Peritransplant Ischemic Injury Triggers Mobilization 
of Stem Cells to Allografts Following Heart 
Transplantation.
Mohamad H. Yamani, Daniel J. Cook, Yang Yu, E. Murat Tuzcu, Norman B. Ratliff, Robert 
Hobbs, Gustavo Rincon, Corinne Bott-Silverman, James B. Young, Nicholas Smedira, 
Randall C. Starling, Cleveland Clinic Foundation, Cleveland, OH
Background: Myocardial ischemia has been shown to trigger mobilization of stem cells 
to the heart in animal experiments.
Objectives: We hypothesized that peri-transplant ischemic injury triggers mobilization of 
stem cells to cardiac allografts following heart transplantation. Gender mismatched heart 
transplants were used for the purpose of the study.
Methods: Between January 1998 and April 2002, a total of 114 male recipients received 
hearts from female donors. Patients underwent serial heart biopsies and annual coronary 
angiograms as per surveillance program. A group of 26 patients had evidence of ischemic 
injury on their initial heart biopsies (Ischemia group). These were compared to the remaining 
88 patients (Control group). Kaplan-Meier survival and freedom from vasculopathy were 
evaluated. Heart biopsy specimens, obtained at one week and one year post transplant, 
were evaluated from 20 patients of each group for the presence of Y chromosome containing 
nuclei (using ﬂuorescent in situ hybridization) and origin of these cells was evidenced by 
double immunoﬂuorescence staining with c-kit suggesting a stem cell origin. SDF mRNA 
and protein expression was evaluated during the ﬁrst 2 weeks after transplantation.
Results: The baseline characteristics of the 2 groups were similar. At one week, Y 
chromosome containing nuclei were signiﬁcantly increased in the Ischemia group (0.68% vs 
0.04%, P<0.0001) compared to the Control group. These were positive for c-kit suggesting 
stem cell origin. A signiﬁcant 3.3 fold increased mRNA expression (P=0.001) and 2.8 fold 
increased protein expression (P=0.01) of SDF was noted in the Ischemia group compared 
to the Control group. At one year, the Y chromosome containing nuclei increased to 0.08% 
in the Control group (P=0.05) and to 1.25% in the Ischemia group (P<0.0001). The Ischemia 
group had poorer 4-year K-M survival (64% vs 85%, P =0.047) and increased vasculopathy 
(5-year K-M freedom from vasculopathy 41% vs 95%, P < 0.001).
Conclusions: Peri-transplant ischemic injury is associated with mobilization of stem cells 
to cardiac allografts. However, poorer survival and worse vasculopathy is noted.
1116-154 Association of Neighborhood Socioeconomic Status 
with Functional Capacity and All Cause Mortality
Mehdi Shishehbor, David Litaker, Claire Pothier, Michael Lauer, Cleveland Clinic 
Foundation, Cleveland, OH, Case Western Reserve University, Cleveland, OH
Background: Residence in a low socioeconomic status (SES) neighborhood predicts 
cardiovascular risk. Poor physical ﬁtness might link lower SES with cardiovascular risk.
Methods: We followed for 5 years 37,554 consecutive patients referred for symptom-
limited stress testing who lived in the state of Ohio, were US citizens, and did not have 
heart failure, atrial ﬁbrillation, valve disease, or pacemakers. Using long-form census data 
based on census blocks (which average 1000 people) we calculated a validated SES 
score. Functional capacity in metabolic equivalents was impaired if in the lowest quartile 
for gender and decades of age. Frailty modeling was used to account for intra-census 
block correlations.
Results: As SES decreased, the likelihood of age- and gender-adjusted impaired 
functional capacity dramatically increased (from highest to lowest quartiles of SES score 
12%, 19%, 26%, 40%, P for trend <0.0001). After adjusting for age, gender, race, body 
mass index, insurance status, cardiac history, diabetes, smoking, hypertension, and use 
of cardiovascular medications, an impaired functional capacity remained associated with 
a lower SES (adjusted odds ratios (95% CI) for decreasing quartiles of SES, 1.34 (1.23-
1.46), 1.76 (1.62-1.91), and 2.45 (2.25-2.67), all P<0.0001). There were 3010 deaths. 
Lower SES was strongly associated with higher death risk (from highest to lowest 
quartiles 5-year death rates 6%, 7%, 9%, 10%, P<0.0001). After adjusting for the same 
confounders along with impaired functional capacity and abnormal heart rate recovery, 
lower SES remained associated with risk of death (adjusted hazard ratios (95% CI) for 
the two lowest quartiles 1.27 (1.14-1.42) and 1.43 (1.28-1.60), all P<0.0001). Despite this 
independence, the magnitude of the association substantially decreased once exercise 
variables were added to a multivariable clinical model.
Conclusions: In this large clinical cohort, a lower SES was strongly and independently 
associated with impaired functional capacity, and increased mortality, even after 
accounting for many possible confounders. Impaired functional capacity might partially 
explain the link between lower SES and increased death risk.
1116-155 Physical Activity Patterns and Health Care Costs
Afshin Ghayoumi, Jonathan Myers, Joshua Abella, Vikram Aleti, Amir Kaykha, Chandra 
Pingili, Victor Froelicher, VA Palo Alto Health Care System/Stanford University, Palo Alto, 
CA, Mercy Medical Center/ UC Davis, Merced, CA
Background: Being physically active is associated with better health outcomes. However, 
the relationship between physical activity patterns and health care costs is unknown.
Methods: Total health care costs and activity status were derived from 404 consecutive 
subjects (mean age 57±14) referred for treadmill testing between 1999 and 2003. Inpatient 
and outpatient health care costs were derived from existing administrative and clinical data 
systems within the Veterans Administration. Univariate and multivariate analyses were 
used to evaluate the association between energy expenditure from weekly recreational 
activity and total health care costs. Multiple regression analysis was performed using 
physical activity, clinical, and historical data to assess determinants of health care costs.
Results: Expressed in tertiles of energy expenditure, active and moderately active subjects 
had lower health care costs than sedentary subjects (p<0.05) (see ﬁgure). In unadjusted 
analysis, the total health care costs were incrementally lower by six percent per 1000 
kcal/week increase in energy expenditure (p<0.001). In multivariate analysis adjusting for 
age, body mass index, activity status, and historical variables, inactivity was found to be 
an independent predictor of cost (p<0.01).
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Conclusion: Inactivity is associated with higher health care costs not explained by the 
sick being less active.
1116-183 Financial and Clinical Factors Associated With the Use 
of Drug Eluting Stents: A Temporal Analysis
David S. Marks, Joseph P. Cummings, Michael J. Oinonen, Hyun J. Yun, Thomas A. 
Ratko, Karl A. Matuszewski, Medical College of Wisconsin, Milwaukee, WI, University 
HealthSystem Consortium, Oak Brook, IL
Background: Drug eluting stents (DES) represent an expensive new technology with 
demonstrated patient beneﬁts. In the United States, the availability of this technology was 
limited in quantity during its introduction. Multiple criteria and guidelines were suggested 
regarding DES implantation in a “rationed” environment. Yet, factors inﬂuencing utilization 
and distribution practices of institutions have not been described.
Methods: The University HealthSystem Consortium (UHC) is an alliance of 90 academic 
health centers in the US. The UHC clinical database was queried for DES implantation 
(DES 527) compared to bare stent implantation in non-AMI patients (DRG 517) for the 
quarters (Q) 2, 3, and 4 of 2003. The UHC database contains a comprehensive collection 
of procedure-speciﬁc data derived from discharge abstract summaries and UB-92 data. 
Institutional and patient descriptors were modeled using univariate and multivariate 
analysis was performed.
Results: 33,174 non-AMI stent procedures were summarized to generate measures for 
82 institutions. DES utilization increased from 24.9±19.1% (Q2) to 64.1±23.4% (Q4), 
an increase of 40.5±25.4% (N=75, paired t-test p<0.0001). Marked variability in the 
penetration of utilization of DES between institutions was observed. In Q2, determinates 
of DES utilization by institution were non-patient related: payor mix and the number of 
discharges from the institution (R2=48.8%, p<0.01). In Q4, the determinates of DES 
utilization were both institution and patient speciﬁc: number of institution discharges, prior 
coronary intervention, diabetes mellitus, and renal failure (R2=31%, p<0.01).
Conclusions: Analysis of the utilization of DES in an environment of limited supply at 
an institutional level demonstrates the use of new technology is affected by non-patient 
criteria in the United States. With greater supply and adoption of DES, patient speciﬁc 
variables become more predictive of institution behavior. Further investigation into 
institution, patient, physician characteristics and the distribution of new technology is 
required to understand the utilization of limited, costly, new advances in patient care.
1116-210 Does Low Molecular Weight Heparin Inﬂuence Outcome 
in Patients With Non ST-segment Elevation Myocardial 
Infarction With or Without Early Revascularization in a 
Real Life Setting?
Ulf Stenestrand, Lars Wallentin, Heart Center, University Hospital Linkoping, Linkoping, 
Sweden, Uppsala Clinical Research Center, Uppsala, Sweden
Background: Low Molecular Weight Heparin (LMWH) has been shown to improve 
outcome in clinical trials when randomizing NSTEMI patients to conservative or early 
revascularization. We investigated the 30-day and 1-year outcome in real life setting for 
NSTEMI patients with or without revascularization within 14 days and the inﬂuence of 
unfractionated heparin (UFH), LMWH, or no type of heparin distributed.
Methods: Prospective cohort study using data from the Register of Information and 
Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA) on patients 
admitted to the coronary care units of 72 Swedish hospitals 1995-2003. 61335 patients 
with AMI as the ﬁnal diagnosis and no ST-segment elevation or LBBB on admission ECG 
were included. 30-day and 1-year mortality data were obtained from the Swedish National 
Cause of Death Register. Relative risk of mortality was calculated by Cox regression 
analysis adjusting for 15 confounding variables.
Results:
30-day mortality 1-year mortality
Therapy Patients unadjusted adj. RR P* unadjusted adj. RR P*
No heparin, no rev.§ 30213 15.6% 1 1 29.9% 1 1
UFH, no rev.§ 4049 11.9% 0.97 0.54 20.7% 0.88 0.001
LMWH, no rev.§ 26619 8.7% 0.72 <0.001 19.2% 0.84 <0.001
No heparin, rev.§ 5441 3.6% 1 1 6.0% 1 1
UFH, rev.§ 1952 4.1% 0.98 0.91 6.5% 0.94 0.58
LMWH, rev.§ 9819 2.2% 0.66 <0.001 4.3% 0.80 0.004
* P-value by Cox regression. § Revascularization within 14 days.
Conclusions: In daily clinical practise LMWH but not UFH is associated with signiﬁcantly 
improved survival both at 30 days and 1 year in NSTEMI patients revascularized within 
14 days. In initially conservatively managed NSTEMI patients both types of heparin are 
associated with improved long term survival.
1116-211 Guaranteeing Quality of Care in Acute Coronary 
Syndromes Using ACC’s GAP Program
Smit C. Vasaiwala, Elizabeth Nolan, Jianming Fang, Eva Kline-Rogers, Sharon Van 
Riper, Gwen Kearly, Richard Otten, Robert Cody, Kim Eagle, University of Michigan 
Hospitals, Ann Arbor, MI
Background: Wide variation exists in the management of acute coronary syndromes 
(ACS). After implementing ACC’s GAP program at our hospital, we sought to determine if 
a real time system for monitoring key quality of care indicators using GAP would improve 
both process indicators and outcomes beyond those of the initial implementation of GAP.
Methods: We evaluated 2634 consecutive patients with ACS admitted to cardiology at our 
hospital between 1/99 and 8/03 (age 63.8 +/- 13.8, male 65%). On 7/02 we began using 
“on ward” chart abstractors to review charts for adherence to the use of GAP standard 
orders and discharge contracts. Using real-time tracking, we contacted patients, doctors 
and nurses to correct any potential noncompliance. We compared patients discharged 
prior to 7/02 (Group 1) and after 7/02 (Group 2) for in-hospital therapy and outcomes, 
and 6 month outcomes.
Results: There were no between group differences in average age, history of MI, CVA, or 
diabetes. There was an increased use of standard evidence based strategies in hospital and 
at time of discharge, better in hospital outcomes, and follow up outcomes in Group 2.
Conclusion: The institution of a formal system to review and “guarantee” key quality 
of care indicators real time in the hospital improves outcomes in patients admitted with 
ACS. The combination of ACC’s GAP program and its real time implementation lead to 
higher use of evidence based therapies and correspondingly better outcomes than those 
associated with the initial GAP implementation.
Group 1
(n=2016)
Group 2
(n=618)
P-
values
In Hospital Therapy (%)
ASA 1934 (95.9) 590 (95.5) 0.615
ACE Inhibitor 1283 (63.6) 472 (76.4) <0.001
Beta Blocker 1807 (89.6) 586 (94.8) <0.001
Statin 1327 (65.8) 494 (79.9) <0.001
PCI 807 (40.0) 276 (44.7) 0.041
In Hospital Outcome (%)
CHF 260 (12.9) 22 (3.6) <0.001
CVA 22 (1.1) 1 (0.2) 0.023
Death 97 (4.8) 26 (4.2) 0.529
Major bleeding 160 (7.9) 11 (1.8) <0.001
Discharge medications
ASA 1742 (90.8) 565 (95.4) <0.001
Beta Blocker 1594 (83.1) 524 (88.5) 0.001
Statin 1304 (68.0) 472 (79.7) <0.001
ACE Inhibitor 1117 (58.2) 403 (68.1) <0.001
Follow up outcomes(%)
Re-hospitalization for heart disease 440 (28.1) 101 (22.6) 0.021
CVA 19 (1.2) 2 (0.5) 0.158
MI 93 (6.0) 16 (3.6) 0.049
Death 155 (9.2) 37 (7.9) 0.373
Death/CVA/MI 256 (15.2) 52 (11.1) 0.024
1116-212 Effect of Pomegranate Juice on Myocardial Perfusion in 
Patients With Coronary Heart Disease: A Randomized, 
Placebo-Controlled Double-Blind Study
Michael D. Sumner, Melanie Elliot-Eller, Gerdi Weidner, Jennifer Daubenmier, Mailine 
H. Chew, Ruth Marlin, Caren Raisin, Dean Ornish, Preventive Medicine Research 
Institute, Sausalito, CA, School of Medicine, University of California, San Francisco, San 
Francisco, CA
Background: Supplementation with polyphenolic antioxidants has been shown to possess 
anti-atherosclerotic properties, such as improved endothelial function. We investigated the 
effects of daily consumption of pomegranate juice (containing 1.5 mmol of total polyphenols) 
for 3 months on myocardial perfusion in patients with ischemic heart disease.
Methods: Forty-ﬁve CHD patients with an ejection fraction > 30% (mean age=68+11; 
89% male; mean BMI = 30+6; 100% on antilipemics) were randomized into an 
experimental group drinking pomegranate juice (240 ml/day; Wonderful variety) or a 
control group drinking a placebo beverage of similar caloric content, ﬂavor and color. 
Participants underwent resting and stress ECG-gated myocardial perfusion SPECT Tc-
99m tetrofosmin scintigraphy at baseline and 3-months. Visual scoring of images using 
standardized segmentation and nomenclature (17 segments, scale of 0-4) was performed 
by a blinded independent nuclear cardiologist. To assess the amount of inducible ischemia, 
the summed difference score (SDS) was calculated by subtracting the summed rest score 
(SRS) from the summed stress score (SSS).
Results: The experimental and control groups showed similar levels of inducible ischemia 
(SDS) at baseline. After three months, the extent of stress-induced ischemia decreased 
among those having consumed pomegranate juice (SDS= -0.7+2.7), while it increased 
in the control group [SDS = 1.2+3.1; F(1, 37) = 4.22, p < 0.05]. Furthermore, there was 
no signiﬁcant change in the SSS or SRS in the experimental group, suggesting that the 
relative improvement of the SDS was not due to the infarction of jeopardized myocardium. 
This beneﬁt was observed without changes in any cardiac medications. Also, there were 
no signiﬁcant increases in blood sugar, hemoglobin A1c, weight or blood pressure.
Conclusions: These results suggest that daily consumption of pomegranate juice may 
improve stress-induced ischemia.
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1116-213 Effects of Peroxisome Proliferator-Activated Receptor 
(PPAR) Ligands on Endothelial Function, Aortic 
Stiffness, and Exercise Tolerance in Patients With 
Coronary Artery Disease and Metabolic Syndrome
Hideki Watanabe, Kunio Nakagawa, Masaaki Kakihana, Kinu Medical Association Hospital, 
Mitsukaido, Japan, Makabe-Silvertopia Facilities for Geriatric Care, Makabe, Japan
Background: Insulin resistance plays an important role in the pathogenesis of coronary 
artery disease (CAD) in patients with metabolic syndrome (MS). We assessed the effects 
of PPAR ligands, pioglitazone (PPAR-γ ligand) and fenoﬁbrate (PPAR-α ligand), on 
endothelial function, aortic stiffness and exercise tolerance in patients with CAD and MS. 
Methods: Forty patients with CAD and MS were randomized to receive PPAR ligands, 
pioglitazone and fenoﬁbrate (PPAR group: n=20) or not to receive PPAR ligands (Control 
group: n=10) after the standard therapy. Flow-mediated dilatation (FMD) and Nitroglycerin-
induced dilatation (NID) of brachial artery were measured by using ultrasound system. We 
also measured aortic pulse wave velocity (PWV) to evaluate aortic stiffness by using 
oscilometric technique (form PWV/ABI®, COLIN) and also assessed exercise tolerance by 
exercise time (ExT) to ST segment depression of 0.10 mV during a treadmill exercise test. 
Insulin resistance was evaluated by HOMA-IR. These measurements were performed at 
baseline, 3 and 6 months after the treatment. 
Results: At baseline, there was no difference in FMD, NID, PWV, ExT, and HOMA-IR 
between two groups. FMD and ExT were signiﬁcantly increased, and PWV and HOMA-IR 
were signiﬁcantly decreased after 6 months in the PPAR group. 
Conclusion: PPAR ligands, pioglitazone and fenoﬁbrate, improve not only insulin 
resistance, but also endothelial function and aortic stiffness, and exercise tolerance in 
patients with CAD and MS.
Baseline 3 months 6 months
FMD (%) PPAR group 3.7 ± 1.4 5.4 ± 1.3*† 8.0 ± 1.4*†
Control group 3.6 ± 1.1 3.9 ± 1.4 4.0 ± 1.6
NIG (%) PPAR group 14.5 ± 1.5 14.7 ± 2.1 14.5 ± 1.5
Control group 14.4 ± 1.4 15.0 ± 3.0 14.4 ± 1.4
PWV (cm/sec) PPAR group 1870 ± 90 1866 ± 105 1560 ± 106*†
Control group 1879 ± 99 1853 ± 131 1796 ± 120
ExT (sec) PPAR group 332 ± 62 338 ± 62 434 ± 63*†
Control group 330 ± 57 334 ± 47 350 ± 51
Data are menas ± SD. *p<0.01 vs Baseline, †p<0.01 vs control group
1116-214 Use of Internal Mammary Arteries in CABG: Does 
Gender Matter?
Phillip Brown, Aaron Kugelmass, Lynn Tarkington, Salvatore Battaglia, Steven Culler, 
Edmund Becker, April W. Simon, Emory University, Atlanta, GA, HCA, Inc., Nashville, TN
Background: The use of the internal mammary arteries (IMA) in coronary artery bypass 
graft (CABG) surgery is widespread, with signiﬁcant improvement in both immediate and 
long term clinical outcomes. We explored whether women undergoing CABG surgery get 
IMA grafts at the same rate as men.
Methods: Using the HCA Casemix database, an administrative database of all consecutive 
admissions in any HCA hospital, all CABG patients (125,960) admitted during the period 
January 1998 through June 2004 who received a CABG (ICD-9 codes 36.01 thru 36.2) 
were analyzed. Patients with IMAs were identiﬁed using ICD-9 codes 36.15 (single IMA) 
or 36.16 (double IMA). Patient characteristics, comorbidities, procedural variables, and 
complications were identiﬁed using ICD-9 codes. Univariate and multivariate regression 
analyses controlling for 27 patient characteristics and comorbid conditions were used 
to analyze whether men were more likely to get an IMA than women. mortality, post-op 
stroke, acute renal failure, and length-of-stay.
Results: Of the 125,960 CABG patients, 79.3% had IMAs. IMA patients, on average, were 
5-years younger than non-IMA patients (65.8 vs. 70.9; p<0.001). Overall, the in-hospital 
mortality rate for IMAs was 2.54% vs. 8.29% for non-IMA patients (p<0.001). Women that 
received an IMA had a mortality rate of 3.63% vs. 9.86% for those not receiving an IMA. 
Univariate results for all outcomes demonstrated signiﬁcant advantages for IMA patients 
versus non-IMA patients. Men were signiﬁcantly more likely to receive and IMA than 
women (81.6% vs. 73.7%; p<0.001). After controlling for patient and co-morbid conditions, 
including age, obesity and previous CABG, multivariate regression results revealed that 
men were 52.7% more like to get an IMA than women.
Conclusions: Decreased utilization of IMA grafts in women may contribute to women’s 
worse outcomes in CABG. As age and co-morbidities do not account for the differences in 
use of IMA grafts, more research as to this bias should be done.
1116-244 Aspirin Resistance in Children With Heart Disease at 
Risk for Thromboembolism: Prevalence and Possible 
Mechanisms
Lisa C. Heistein, William A. Scott, Thomas M. Zellers, David E. Fixler, Claudio 
Ramaciotti, Janna M. Journeycake, Matthew S. Lemler, The University of Texas 
Southwestern Medical Center & Children’s Medical Center, Dallas, TX
Background: Aspirin is used to prevent thromboembolic complications in children with 
heart disease despite lack of scientiﬁc evidence to support its efﬁcacy. Studies in adults 
report a 5-40% prevalence of aspirin resistance, yet the mechanisms involved are poorly 
understood. Our aims were to determine the prevalence of aspirin resistance and explore 
its possible mechanisms in a pediatric cardiac population.
Methods: This was a prospective, cross-sectional study of 80 patients who routinely 
receive aspirin, including cyanotic children with single ventricle palliation and acyanotic 
children after transcatheter device or stent placement or ablation. Platelet aggregation 
was measured by Platelet Function Analyzer (PFA)-100 using collagen/epinephrine 
(CEPI) and collagen/ADP (CADP) coated cartridges to measure closure times in seconds 
(s). Aspirin resistance was deﬁned as having a normal CEPI closure time (< 187 s) after 
aspirin administration. Urinary excretion of 11-dehydro-thromboxane B2 (11-dTXB2), a 
metabolite reﬂecting thromboxane production, was measured to further explore possible 
mechanisms of resistance in 25 of the patients.
Results: The prevalence of aspirin resistance was 33.8%. Median (range) CADP closure 
time was also shorter for aspirin-resistant (78.5, 60-115 s) than for aspirin-sensitive 
patients (103, 60-240 s), p< 0.001. There was no difference between the aspirin-sensitive 
and resistant groups for baseline 11-dTXB2, 4,147 (1,024-10,132) vs. 2,053 (993-35,227) 
pg/mg creatinine (p= 0.59), 11-dTXB2 after aspirin administration, 968 (173-3,416) vs. 
869 (359-5,073) pg/mg creatinine (p= 0.82), or decrease in 11-dTXB2, 67.9% vs. 64.8% 
(p= 0.97). There was no correlation between CEPI closure time and 11-dTXB2 following 
aspirin administration (r= 0.25) or decrease in 11-dTXB2 (r= 0.02).
Conclusion: Approximately one-third of children with heart disease demonstrated aspirin 
resistance. Our ﬁndings suggest that resistance is not entirely due to lack of inhibition of 
platelet thromboxane production. Alternative sources of thromboxane and thromboxane-
independent mechanisms, such as ADP-induced platelet activation, may contribute to 
aspirin resistance.
1116-264 Adenosine-Insensitive Right Ventricular Tachycardia: 
Forme Fruste of Arrhythmogenic Right Ventricular 
Dysplasia ?
Ravi K. Yarlagadda, Sei Iwai, Jim Cheung, Suneet Mittal, Steven M. Markowitz, Kenneth 
M. Stein, Bindi K. Shah, Vivian Tan, Bruce B. Lerman, Cornell University Medical Center, 
New York, NY
Background: Right ventricular tachycardias are primarily due to either right ventricular 
outﬂow tract tachycardia (RVOT) or arrhythmogenic right ventricular dysplasia (ARVD). The 
response of adenosine is often useful in distinguishing between ventricular tachycardia (VT) 
due to these two entities. We have identiﬁed a unique subset of patients (pts) with RVOT 
tachycardia who have a distinct phenotype and who are adenosine-insensitive. The purpose 
of this study was to compare and contrast the clinical and electrophysiological characteristics 
of the pts with adenosine-insensitive RVOT tachycardia and those with ARVD.
Methods and Results: A standard electrophysiological study as well as electroanatomic 
mapping was performed, during which VT was induced and adenosine administered. Six 
pts had RVOT tachycardia; the mean age of 56 ± 14 years, and EF of 61 ± 7%. Ten pts 
had ARVD; the mean age was 43 ± 15 years and EF was 55 ± 9%. We compared the 
following variables: a) baseline ECG b) MRI c) catecholamine facilitation d) number of 
morphologies of VT induced and e) ﬁndings during mapping and ablation. MRI imaging 
did not differentiate between the two groups (p=NS), nor did catecholamine facilitation 
(p=NS). Pts with ARVD had an abnormal resting ECG (9/10), macroreentry circuits 
as deﬁned by 3D electroanatomic mapping, presence of fractionated electrograms, 
multiple morphologies of VT induced and VT that could be entrained. In contrast, pts with 
adenosine-insensitive RVOT tachycardia had a normal resting ECG (10/10), VT of focal 
origin, absence of fractionated electrograms, and VT that could not be entrained. Of note, 
two of these six pts were found to have a somatic mutation in the inhibitory G-protein G�i, 
resulting in impaired intracellular cyclic AMP regulation.
Conclusions: These ﬁndings identify a new group of RVOT pts who are adenosine-
insensitive and who have an electrophysiological proﬁle that differs from those with ARVD. 
Distinguishing between these pts is based on establishing whether the arrhythmia is focal 
and due to a nonreentrant mechanism.
1116-265 Cardiac Resynchronization Therapy for Patients 
with End Stage Heart Failure Listed for Cardiac 
Transplantation
Maninder S. Bedi, Vishal Gujral, Samir Saba, Ogundu Ngwu, Michael Mathier, 
Dennis McNamara, Linda Cadaret, Robert Kormos, Srinivas Murali, UNIVERSITY OF 
PITTSBURGH, PITTSBURGH, PA
Background: Mortality among heart failure (HF) patients (pts) listed for cardiac 
transplantation (CTx) is high. We have previously reported that internal cardioverter 
deﬁbrillator (ICD) therapy is an effective “bridge” to CTx. We sought to analyze if cardiac 
resynchronization therapy (CRT) in addition to ICD provided added beneﬁt. METHODS: 
From January 2001 to July 2003, 211 pts (age 55± 11 years, 72% male, LVEF 0.24±0.09, 
51% ischemic, NYHA III/IV: 68%/21% , Peak VO2 9.2±7.6 ml/kg/min) were actively 
listed for CTx. All pts were on optimal medical therapy (OMT). In addition,15 (7%) pts 
received CRT+ICD, and 101 (48%) pts recieved ICD. The remaining 95 (45%) pts were 
on OMT alone. Event (death or need for ventricular assist device) free survival to CTx 
was compared by Kaplan Meier method and ANOVA was used to compare event rates 
in the 3 groups. 
Results: Demographics, hemodynamics, etiology of HF, LVEF, peak VO2 and NYHA 
class were comparable in the 3 groups. Event free survival to CTx was improved in pts 
with CRT+ICD compared to the ICD and OMT only groups (CRT/ICD/OMT: 1 year = 
92/89/86%, 2 year = 92/86/83%, p=0.07). Event free survival to CTx was better in pts 
on device therapy (CRT or ICD) compared to OMT only (1 yr =94/88%, 2 yr = 91%/83%; 
p=0.02). The event rate was lower in pts with CRT+ICD (6.9%) compared to ICD (11.9%) 
or OMT only (22.1%) groups (p=0.03).
CONCLUSIONS: 1) Both CRT+ICD and ICD alone provide an effective “bridge” to CTx in 
advanced HF pts.2) The addition of CRT to ICD further lowers the event rate in these pts. 
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Patients with Congestive Heart Failure
Daniel M. Bloomﬁeld, J. Thomas Bigger, Jr., Pearila Namerow, Richard Steinman, 
Michael Parides, TWA in CHF Investigators, Columbia University, New York, NY
We conducted a prospective longitudinal study to test the hypothesis that T wave alternans 
(TWA) is associated with an increased rate of arrhythmic events (AE) in patients with EF 
< 0.41. We previously reported that in a subset who met the MADIT II criteria, a TWA test 
identiﬁes not only a high risk group, but also a low risk group unlikely to beneﬁt from ICD 
therapy. In this report, we present the results of the entire study (including patients with 
ischemic (ISC) and non-ischemic (N-ISC) heart disease).
Methods. Patients were eligible for this study if they had an EF < 0.41, were in sinus rhythm, 
had no history of a prior sustained AE, and were NYHA I-III. All patients underwent a TWA 
exercise test. Our composite endpoint includes all-cause mortality and non-fatal AE.
Results. We studied 549 patients; 49% had ISC, the mean EF was 0.25, and 66% had 
an abnormal (positive or indeterminate) TWA test. Patients were followed for 2 years 
(average follow-up 20 months.) There were 51 endpoints (40 deaths and 11 non-fatal AE). 
Comparing patients with a normal to those with an abnormal TWA test, the hazard ratio for 
the composite endpoint was 6.5 (p < 0.001). The false negative rate of TWA was only 2%. 
The association between TWA and the composite endpoint was strong among patients 
with both ISC and N-ISC heart disease. 
Conclusion. Among patients with EF < 0.41 (ISC or N-ISC), TWA can identify a group 
at high risk of death or non-fatal AE, as well as a low risk group, which is likely to survive 
without an AE.
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